<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1510200212
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Emcap
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Capecitabine
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        556.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EMCAP belongs to the group of medicines called &quot;cytostatic medicines&quot;, which stop the growth of cancer cells. EMCAP contains capecitabine, which itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an active anti-cancer medicine (more in tumour tissue than in normal tissue).</p><p>EMCAP is used in the treatment of colon, rectal, gastric, or breast cancers.<br />Furthermore, EMCAP is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery.<br />EMCAP may be used either alone or in combination with other medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take EMCAP</strong></p><ul><li><p>If you are allergic to capecitabine or any of the other ingredients of this medicine (listed in</p><p>section 6). You must inform your doctor if you know that you have an allergy or over reaction</p><p>to this medicine,</p></li><li><p>If you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer&nbsp;medicines such as fluorouracil),</p></li><li><p>If you are pregnant or breast-feeding,</p></li><li><p>If you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia&nbsp;or thrombocytopenia),</p></li><li><p>If you have severe liver or kidney problems,</p></li><li><p>If you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase&nbsp;(DPD)</p></li><li><p>If you are being treated now or have been treated in the last 4 weeks with brivudine, sorivudine&nbsp;or similar classes of substance as part of herpes zoster (chickenpox or shingles) therapy.</p></li></ul><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking EMCAP</p><ul><li><p>If you know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine</p><p>dehydrogenase (DPD)</p></li><li><p>If you have liver or kidney diseases</p></li><li><p>If you have or had heart problems (for example an irregular heartbeat or pains to the chest jaw</p><p>and back brought on by physical effort and due to problems with the blood flow to the heart)</p></li><li><p>If you have brain diseases (for example. cancer that has spread to the brain, or nerve damage</p><p>(neuropathy)</p></li><li><p>If you have calcium imbalances (seen in blood tests)</p></li><li><p>If you have diabetes</p></li><li><p>If you cannot keep food or water in your body because of severe nausea and vomiting</p></li><li><p>If you have diarrhoea</p></li><li><p>If you are or become dehydrated</p></li><li><p>If you have imbalances of ions in your blood (electrolyte imbalances, seen in tests)</p></li><li><p>If you have a history of eye problems as you may need extra monitoring of your eyes</p></li><li>&nbsp; &nbsp;If you have a severe skin reaction.</li></ul><p><strong>DPD deficiency:</strong>&nbsp;DPD deficiency is a rare condition present at birth that is not usually associated with health problems unless you receive certain medicines. If you have an unrecognised DPD deficiency and take EMCAP, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects. Contact your doctor immediately if you are concerned about any of the side effects or if you notice any additional side effects not listed in the leaflet (see section 4 Possible side effects).</p><p><strong>Children and adolescents</strong></p><p>EMCAP is not indicated in children and adolescents. Do not give EMCAP to children and adolescents.</p><p><strong>Other medicines and EMCAP</strong></p><p>Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines.</p><p>&nbsp;</p><p><strong>You must not take brivudine (an anti-viral medicines for treatment of shingles or chickenpox) at the same time as capecitabine treatment (including during any rest periods when you are not taking any capecitabine tablets).</strong></p><p><strong>If you have taken brivudine you must wait for at least 4 weeks after stopping brivudine before starting to take capecitabine. See also section &ldquo;Do not take EMCAP&rdquo;.</strong></p><p>Also, you need to be particularly careful if you are taking any of the following:</p><ul><li><p>gout medicines (allopurinol),</p></li><li><p>blood-thinning medicines (coumarin, warfarin),</p></li><li><p>medicines for seizures or tremors (phenytoin),</p></li><li><p>interferon alpha,</p></li><li><p>radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab,</p><p>cisplatin, irinotecan),</p></li><li><p>medicines used to treat folic acid deficiency.</p><p><strong>EMCAP with food and drink</strong></p><p>You should take EMCAP no later than 30 minutes after meals.</p><p><strong>Pregnancy, breast-feeding and pregnancy</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You must not take EMCAP if you are pregnant or think you might be.<br />You must not breast-feed if you are taking EMCAP and for 2 weeks after the last dose.</p><p>If you are a male patient and your female partner could become pregnant, you should use effective contraception during treatment with EMCAP and for 3 months after the last dose.</p><p><strong>Driving and using machines</strong></p><p>EMCAP may make you feel dizzy, nauseous or tired. It is therefore possible that EMCAP could affect your ability to drive a car or operate machines.</p><p><strong>EMCAP contains anhydrous lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />EMCAP should only be prescribed by a doctor experienced in the use of anticancer medicines.</p><p>Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of EMCAP is based on your body surface area. This is calculated from your height and weight. The usual dose for adults is 1250 mg/m2&nbsp;of body surface area taken two times daily (morning and evening). Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2&nbsp;and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2&nbsp;and should take 5 tablets of 500 mg two times daily.</p><p>Your doctor will tell you what dose you need to take, when to take it and for how long you need to take it.</p><p>Your doctor may want you to take a combination of 150 mg and 500 mg tablets for each dose.</p><ul><li><p>Take the tablets&nbsp;morning and evening&nbsp;as prescribed by your doctor.</p></li><li><p>Take the tablets within&nbsp;30 minutes after the end of a meal&nbsp;(breakfast and dinner)&nbsp;and swallow&nbsp;whole with water. Do not crush or cut tablets. If you cannot swallow EMCAP tablets&nbsp;whole, tell your healthcare provider.</p></li><li><p>It is important that you take all your medicine as prescribed by your doctor.<br />EMCAP tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken). This 21 day period is one treatment cycle.<br />In combination with other medicines the usual dose for adults may be less than 1250 mg/m2&nbsp;of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).</p><p><strong>If you take more EMCAP than you should</strong></p><p>If you take more EMCAP than you should, contact your doctor as soon as possible before taking the next dose.<br />You might get the following side effects if you take a lot more capecitabine than you should: feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells). Tell your doctor immediately if you experience any of these symptoms.</p><p><strong>If you forget to take EMCAP</strong></p><p>Do not take the missed dose at all. Do not take a double dose to make up for a forgotten dose. Instead, continue your regular dosing schedule and check with your doctor.</p></li></ul><p>&nbsp;</p><ul><li><strong>If you stop taking EMCAP</strong></li></ul><p>There are no side effects caused by stopping treatment with capecitabine. In case you are using coumarin anticoagulants (containing e.g. phenprocoumon), stopping capecitabine might require that your doctor adjusts your anticoagulant dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;STOP&nbsp;taking EMCAP immediately and contact your doctor if any of these symptoms occur:</p><ul><li><p>Diarrhoea:&nbsp;if you have an increase of 4 or more bowel movements compared to your normal</p><p>bowel movements each day or any diarrhoea at night.</p></li><li><p>Vomiting:&nbsp;if you vomit more than once in a 24-hour time period.</p></li><li><p>Nausea:&nbsp;if you lose your appetite, and the amount of food you eat each day is much less than</p><p>usual.</p></li><li><p>Stomatitis:&nbsp;if you have pain, redness, swelling or sores in your mouth and/or throat.</p></li><li><p>Hand-and-foot skin-reaction: if you have pain, swelling, redness or tingling of hands and/or</p><p>feet</p></li><li><p>Fever:&nbsp;if you have a temperature of 38&deg;C or greater.</p></li><li><p>Infection:&nbsp;if you experience signs of infection caused by bacteria or virus, or other organisms.</p></li><li><p>Chest pain:&nbsp;if you experience pain localised to the centre of the chest, especially if it occurs</p><p>during exercise.</p></li><li><p>Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads and</p><p>blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.</p></li><li><p>DPD Deficiency:&nbsp;if you have a known DPD deficiency, you are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by EMCAP (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity).</p><p>If caught early, these side effects usually improve within 2 to3 days after treatment discontinuation. If these side effects continue, however, contact your doctor immediately. Your doctor may instruct you to restart treatment at a lower dose.</p><p>Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your identification by fingerprint scan.<br />In addition to the above, when EMCAP is used alone, very common side effects, which may affect more than 1 in 10 people are:</p></li><li><p>abdominal pain</p></li><li><p>rash, dry or itchy skin</p></li><li><p>tiredness</p></li><li><p>&nbsp;loss of appetite (anorexia)</p><p>These side effects can become severe; therefore, it is important that you&nbsp;always contact your doctor immediately&nbsp;when you start to experience a side effect. Your doctor may instruct you to decrease the dose and/or temporarily discontinue treatment with EMCAP. This will help reduce the likelihood that the side effect continues or becomes severe.</p><p>Other side effects are:</p></li></ul><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people) include:</strong></p><ul><li>decreases in the number of white blood cells or red blood cells (seen in tests)</li><li><p>dehydration, weight loss</p></li><li><p>sleeplessness (insomnia), depression</p></li><li><p>headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling&nbsp;sensation), taste changes</p></li><li><p>eye irritation, increased tears, eye redness (conjunctivitis)</p></li><li><p>inflammation of the veins (thrombophlebitis),</p></li><li><p>shortness of breath, nose bleeds, cough, runny nose</p></li><li><p>cold sores or other herpes infections</p></li><li><p>infections of the lungs or respiratory system (e.g. pneumonia or bronchitis)</p></li><li><p>bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind, dry&nbsp;mouth</p></li><li><p>skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin discolouration,&nbsp;skin loss, skin inflammation, nail disorder</p></li><li><p>pain in the joints, or in the limbs (extremities), chest or back</p></li><li><p>fever, swelling in the limbs, feeling ill</p></li><li><p>problems with liver function (seen in blood tests) and increased blood bilirubin (excreted by&nbsp;the liver)</p></li><li><p>&nbsp;</p><p>&nbsp;</p><strong>Uncommon side effects (may affect up to 1 in 100 people) include:</strong></li><li><p>blood infection, urinary tract infection, infection of the skin, infections in the nose and throat,&nbsp;fungal infections (including those of the mouth), influenza, gastroenteritis, tooth abscess</p></li><li><p>lumps under the skin (lipoma)</p></li><li><p>decreases in blood cells including platelets, thinning of blood (seen in tests)</p></li><li><p>allergy</p></li><li><p>diabetes, decrease in blood potassium, malnutrition, increased blood triglycerides</p></li><li><p>confusional state, panic attacks, depressed mood, decreased libido</p></li><li><p>difficulty speaking, impaired memory, loss of movement coordination, balance disorder,&nbsp;fainting, nerve damage (neuropathy) and problems with sensation</p></li><li><p>blurred or double vision</p></li><li><p>vertigo, ear pain</p></li><li><p>irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)</p></li><li><p>blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs (extremities),&nbsp;purple spots on the skin</p></li><li><p>blood clots in the veins in the lung (pulmonary embolism), collapsed lung, coughing up blood,&nbsp;asthma, shortness of breath on exertion</p></li><li><p>bowel obstruction, collection of fluid in the abdomen, inflammation of the small or large&nbsp;intestine, the stomach or the oesophagus, pain in the lower abdomen, abdominal discomfort,&nbsp;heartburn (reflux of food from the stomach), blood in the stool</p></li><li><p>jaundice (yellowing of skin and eyes)</p></li><li><p>skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling or pain&nbsp;of the face</p></li><li><p>joint swelling or stiffness, bone pain, muscle weakness or stiffness</p></li><li><p>fluid collection in the kidneys, increased frequency of urination during the night, incontinence,&nbsp;blood in the urine, increase in blood creatinine (sign of kidney dysfunction)</p></li><li><p>unusual bleeding from the vagina</p></li><li><p>swelling (oedema), chills and rigors</p><p>&nbsp;</p></li></ul><p><strong>Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer. </strong></p><p><strong>Other side-effects seen in this setting are the following:</strong></p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people) include:</p><ul><li><p>decrease in blood sodium, magnesium or calcium, increase in blood sugar</p></li><li><p>nerve pain</p></li><li><p>ringing or buzzing in the ears (tinnitus), loss of hearing</p></li><li><p>vein inflammation</p></li><li><p>hiccups, change in voice</p></li><li><p>pain or altered/abnormal sensation in the mouth, pain in the jaw</p></li><li><p>sweating, night sweats</p></li><li><p>muscle spasm</p></li><li><p>difficulty in urination, blood or protein in the urine</p></li><li><p>bruising or reaction at the injection site (caused by medicines given by injection at the same&nbsp;time)</p></li></ul><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people) include:</p><ul><li>&nbsp;</li><li><p>narrowing or blockage of tear duct (lacrimal duct stenosis)</p></li><li><p>liver failure</p></li><li><p>inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis)</p></li><li><p>specific changes in the electrocardiogram (QT prolongation)</p></li><li><p>certain types of arrhythmia (including ventricular fibrillation, torsade de pointes, and bradycardia)</p></li><li><p>eye inflammation causing eye pain and possibly eyesight problems</p></li><li><p>inflammation of the skin causing red scaly patches due to an immune system illness</p><p><br /><br />Very rare side effects (may affect up to 1 in 10,000 people) include:</p></li><li><p>severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of&nbsp;the mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes)</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not store above 30oC.&nbsp;Protect from light.<br />Do not use this medicine after the expiry date which is stated on the outer carton and label after EXP.<br />The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is capecitabine. Each film coated tablet contains 500 mg of capecitabine</p><p>The other ingredients are:</p><p>Tablet Core:&nbsp;Microcrystalline cellulose (PH 101), Anhydrous Lactose, Croscarmellose Sodium, Hydroxypropyl Methylcellulose, Magnesium stearate.</p><p>Tablet coating:&nbsp;Opadry Brown 03A565005</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Light peach to peach colored, oblong shaped biconvex film coated tablets, debossed with "C" on one side and "500" on other side. 10 tablets of EMCAP are packed in Alu-Alu blister pack

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tadawi Biomedical Company,</p><p>Sudair Industrial Zone,</p><p>Sudair,</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي&nbsp;<strong>إمكاب</strong>&nbsp;إلى مجموعة الأدوية التي تسمى &quot;الأدوية المثبطة للخلايا&quot;، التي توقف نمو الخلايا السرطانية. يحتوي&nbsp;<strong>إمكاب</strong>&nbsp;على كابيسيتابين، وهو بحد ذاته ليس دواء لتثبيط الخلايا. فقط بعد أن يمتصه الجسم، فإنه يتحول إلى دواء فعال مضاد للسرطان (أكثر فاعلية في أنسجة الورم من الأنسجة الطبيعية).</p><p dir="RTL">يستخدم&nbsp;<strong>إمكاب</strong>&nbsp;في علاج سرطانات القولون, المستقيم, المعدة, أو الثدي.</p><p dir="RTL">علاوة على ذلك، يستخدم&nbsp;<strong>إمكاب</strong>&nbsp;لمنع حدوث سرطان القولون من جديد بعد إزالة الورم كاملاً عن طريق الجراحة.</p><p dir="RTL">يمكن استخدام&nbsp;<strong>إمكاب</strong>&nbsp;إما بمفرده أو بالمشاركة مع الأدوية الأخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ إمكاب:</strong></p><p dir="RTL">&bull; إذا كان لديك حساسية تجاه كابيسيتابين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6). يجب عليك إبلاغ طبيبك إذا كنت تعرف أن لديك حساسية أو رد فعل زائد لهذا الدواء،</p><p dir="RTL">&bull; إذا حدث معك سابقاً ردود فعل شديدة أثناء المعالجة بالفلوروبايريدين (مجموعة من أدوية مضادة للسرطان مثل فلورويوراسيل)،</p><p dir="RTL">&bull; إذا كنتِ حاملاً أو مرضعةً</p><p dir="RTL">&bull; إذا كان لديك مستويات منخفضة للغاية من الخلايا البيضاء أو الصفيحات في الدم (قلة الكريات البيضاء، قلة العدلات, أو قلة الصفيحات)،</p><p dir="RTL">&bull; إذا كان لديك مشاكل حادة في الكبد أو الكلى،</p><p dir="RTL">&bull; إذا كنت تعلم أنه ليس عندك أي نشاط لأنزيم ديهايدروبيريميدين دِهايدروجيناز (DPD),</p><p dir="RTL">&bull; إذا كنت تُعالَج حالياً أو أنك قد عولجت في الأربعة أسابيع الماضية بمادة بريڤودين, سوريڤودين أو فئات مماثلة لهذه المادة كجزء من علاج داء المنطقة (جدري الماء أو القوباء المنطقية),</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول&nbsp;<strong>إمكاب</strong>:</p><p dir="RTL">&bull; إذا كنت تعرف أن لديك نقصاً جزئياً في نشاط إنزيم ديهايدروبيريميدين دِهايدروجيناز (DPD),</p><p dir="RTL">&bull; إذا كان لديك أمراض في الكبد أو الكلى,</p><p dir="RTL">&bull; إذا كان لديك حالياً أو سابقاً مشاكل في القلب (مثل: عدم انتظام ضربات القلب أو آلام في فك الصدر والظهر بسبب الجهد البدني وبسبب مشاكل في تدفق الدم إلى القلب),</p><p dir="RTL">&bull; إذا كان لديك أمراض في الدماغ (مثل، سرطان منتشر إلى المخ، أو تلف أعصاب (اعتلال عصبي),</p><p dir="RTL">&bull; إذا كان لديك اختلال في الكالسيوم (تظهر في اختبارات الدم),</p><p dir="RTL">&bull; إذا كان لديك مرض السكري,</p><p dir="RTL">&bull; إذا كنت لا تستطيع الاحتفاظ بالطعام أو الماء في جسمك بسبب الغثيان الشديد والقيء,</p><p dir="RTL">&bull; إذا كان لديك إسهال,</p><p dir="RTL">&bull; إذا كان لديك جفاف أو أصبح عندك جفاف,</p><p dir="RTL">&bull; إذا كان لديك اختلال في أيونات دمك (اختلال توازن بالكهارب، تظهر في الفحوصات),</p><p dir="RTL">&bull; إذا كان لديك تاريخ سابق لمشاكل عينية فقد تحتاج إلى مراقبة خاصة لعينيك,</p><p dir="RTL">&bull; إذا كان لديك رد فعل جلدي شديد.</p><p dir="RTL"><strong><em>نقص الـ&nbsp;</em></strong><strong><em>DPD</em></strong><strong><em>:</em></strong>&nbsp;نقص الديهايدروبيريميدين دِهايدروجيناز&nbsp;DPD&nbsp;هو حالة نادرة موجودة عند الولادة ولا ترتبط عادة بالمشاكل الصحية ما لم تتلقى أدوية معينة. إذا كان لديك نقصاً غير معروفٍ للـ&nbsp;DPD&nbsp;&nbsp;وأخذت&nbsp;<strong>إمكاب</strong>، فأنت في خطر متزايد للإصابة المبكرة بأشكال حادة من التأثيرات الجانبية المدرجة في القسم 4 &quot;تأثيرات جانبية محتملة&quot;,</p><p dir="RTL">اتصل بطبيبك على الفور إذا كنت تشعر بقلق إزاء أي من التأثيرات الجانبية أو إذا لاحظت أية تأثيرات جانبية إضافية غير مدرجة في النشرة (انظر القسم 4 &quot;تأثيرات جانبية محتملة&quot;).</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا يوصف&nbsp;<strong>إمكاب</strong>&nbsp;للأطفال والمراهقين. لا تُعطي&nbsp;<strong>إمكاب</strong>&nbsp;للأطفال والمراهقين.</p><p dir="RTL"><strong>الأدوية الأخرى وإمكاب</strong></p><p dir="RTL">قبل بدء العلاج، أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو قد أخذت مؤخراً أو قد تأخذ أية أدوية أخرى. وهذا مهم للغاية، حيث إن تناول أكثر من دواء واحد بنفس الوقت يمكن أن يُقوّي أو يُضعِف تأثير الأدوية,</p><p dir="RTL"><strong>يجب ألا تأخذ بريڤودين (أدوية مضادة للفيروسات لعلاج القوباء المنطقية أو جدري الماء) بنفس الوقت مع علاج مثل كابيسيتابين (بما في ذلك خلال أية فترات راحة عندما لا تتناول أية أقراص من كابيسيتابين).</strong></p><p dir="RTL"><strong>إذا كنت قد أخذت بريڤودين يجب عليك الانتظار مدة 4 أسابيع على الأقل بعد إيقاف بريڤودين قبل البدء بتناول كابيسيتابين. انظر أيضاً القسم &quot;لا تأخذ إمكاب&quot;.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أيضاً، يجب أن تحرص بشكل خاص إذا كنت تأخذ أيّاً مما يلي:</p><p dir="RTL">&bull; أدوية النقرس (الوبورينول)،</p><p dir="RTL">&bull; أدوية مميعة للدم (كومارين، وارفارين)،</p><p dir="RTL">&bull; أدوية النوبات أو الهزات (فينيتوئين)،</p><p dir="RTL">&bull; إنترفيرون ألفا،</p><p dir="RTL">&bull; علاج إشعاعي وبعض الأدوية المستخدمة لعلاج السرطان (حمض فولينيك, أوكساليبلاتين، بيڤاسيزوماب، سيسبلاتين، إرينوتيكان)،</p><p dir="RTL">&bull; أدوية مستخدمة لعلاج نقص حمض الفوليك.</p><p dir="RTL"><strong>إمكاب مع الطعام والشراب</strong></p><p dir="RTL">يجب أن تأخذ&nbsp;<strong>إمكاب</strong>&nbsp;بموعد لا يتجاوز 30 دقيقة بعد وجبات الطعام.</p><p dir="RTL"><strong>الحمل, الرضاعة الطبيعية والحمل</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعةً، تظنين أنكِ قد تكوني حاملاً أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء. يجب أن لا تأخذي&nbsp;<strong>إمكاب</strong>&nbsp;إذا كنتِ حاملا أو تظنين أنكِ كذلك.</p><p dir="RTL">يجب أن لا تُرضعي إذا كنتِ تتناولين&nbsp;<strong>إمكاب</strong>&nbsp;ولمدة أسبوعين بعد آخر جرعة.</p><p dir="RTL">إذا كنتَ مريضاً ذَكَراً ويمكن أن تصبح شريكتك الأنثى حاملاً، يجب عليك استخدام موانع حمل فعالة أثناء العلاج بدواء&nbsp;<strong>إمكاب</strong>&nbsp;ولمدة 3 أشهر بعد آخر جرعة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك&nbsp;<strong>إمكاب</strong>&nbsp;تشعر بالدوار أو الغثيان أو التعب. فمن الممكن عندئذ أن يؤثر&nbsp;<strong>إمكاب</strong>&nbsp;على قدرتك في قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL"><strong>يحتوي إمكاب على اللاكتوز اللامائي</strong></p><p dir="RTL">إذا أخبرك طبيبك بأنك لا تتحمل بعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً تماماً كما أخبرك طبيبك أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">يجب أن يوصف&nbsp;<strong>إمكاب&nbsp;</strong>فقط من قبل طبيب ذو خبرة باستخدام الأدوية المضادة للسرطان.</p><p dir="RTL">سيصف طبيبك الجرعة والعلاج المناسب لك. تعتمد جرعة&nbsp;<strong>إمكاب&nbsp;</strong>على مساحة سطح جسمك. ويُحسب ذلك من طولك ووزنك. الجرعة المعتادة للبالغين هي 1250 ملغ/م2 من مساحة سطح الجسم تؤخذ مرتين يومياً (صباحاً ومساءً).</p><p dir="RTL">فيما يلي مثالان:</p><p dir="RTL">- الشخص الذي يبلغ وزن جسمه 64 كغ وطوله 1,64 متراً لديه مساحة سطح جسم 1,7 م2 ويجب أن يأخذ 4 أقراص من عيار 500 ملغ وقرص واحد من عيار 150 ملغ مرتان يومياً.</p><p dir="RTL">- الشخص الذي يبلغ وزن جسمه 80 كغ وطوله 1,80 متراً لديه مساحة سطح جسم 2,00م2 ويجب أن يأخذ 5 أقراص&nbsp;&nbsp;من عيار 500 ملغ مرتان يومياً.</p><p dir="RTL"><strong>سيخبرك طبيبك بالجرعة التي تحتاجها، وموعد تناولها، ولأي مدة أنت بحاجة لأخذها.&nbsp;</strong></p><p dir="RTL">قد يرتأي طبيبك أن تأخذ خليطاً من أقراص 150 ملغ و 500 ملغ لكل جرعة.</p><p dir="RTL">&bull; تناول أقراصك في&nbsp;<strong>الصباح والمساء</strong>&nbsp;كما وصفها طبيبك.</p><p dir="RTL">&bull; خذ الأقراص في غضون&nbsp;<strong>30 دقيقة بعد نهاية الوجبة</strong>&nbsp;(الإفطار والعشاء)&nbsp;<strong>وابلعها بالكامل مع الماء</strong>.&nbsp;<strong>لا تسحق أو تقطع الأقراص. إذا لم تستطع بلع أقراص إمكاب بكاملها، أخبر مقدم الرعاية الصحية الخاص بك.</strong></p><p dir="RTL">&bull; من المهم أن تتناول دواءك كاملاً كما وصفه لك طبيبك.</p><p dir="RTL">تؤخذ أقراص&nbsp;<strong>إمكاب&nbsp;</strong>عادةً<strong>&nbsp;</strong>&nbsp;لمدة 14 يوماً تليها فترة راحة لمدة 7 أيام (حيث لا تأخذ أقراص). هذه الفترة لمدة 21 يوماً هي دورة علاج واحدة.</p><p dir="RTL">بالمشاركة مع الأدوية الأخرى، قد تقل الجرعة المعتادة للبالغين عن 1250 ملغ/م2 من مساحة سطح الجسم، وقد تحتاج إلى تناول الأقراص على مدى فترة زمنية مختلفة (مثلاً: كل يوم، بدون فترة راحة).</p><p dir="RTL"><strong>إذا أخذت إمكاب أكثر مما يجب</strong></p><p dir="RTL">إذا أخذت&nbsp;<strong>إمكاب&nbsp;</strong>أكثر مما يجب، اتصل بطبيبك بأسرع ما يمكن قبل تناول الجرعة التالية.</p><p dir="RTL">قد تتعرض للتأثيرات الجانبية التالية إذا أخذت كابيسيتابين أكثر بكثير مما يجب: شعور بأنك مريض, إسهال, التهاب أو تقرح أمعاء أو فم, ألم أو نزيف من الأمعاء أو المعدة, أو انخفاض في النخاع العظمي (نقص في أنواع معينة من خلايا الدم). أخبر طبيبك فوراً إذا عانيت من أي من هذه الأعراض.</p><p dir="RTL"><strong>إذا نسيت أن تأخذ إمكاب</strong></p><p dir="RTL">لا تأخذ الجرعة الفائتة إطلاقاً. لا تأخذ جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL">بدلاً من ذلك، تابع جدولك الزمني للجرعات بانتظام واستشر طبيبك.</p><p dir="RTL"><strong>إذا توقفت عن تناول إمكاب</strong></p><p dir="RTL">لا يوجد أية تأثيرات جانبية ناجمة عن وقف المعالجة بمادة كابيسيتابين. وفي حالة استخدامك مضادات التخثر الكومارينية (الحاوية مثلاً على فينبروكومون)، قد يتطلب إيقاف كابيسيتابين أن يقوم طبيبك بتعديل جرعة مضاد التخثر.</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء تأثيرات جانبية، ولو أنها لا تحصل لدى كل شخص.</p><p dir="RTL"><strong>توقَّف</strong>&nbsp;عن تناول&nbsp;<strong>إمكاب</strong>&nbsp;على الفور واتصل بطبيبك في حالة حدوث أي من هذه الأعراض:</p><p dir="RTL">&bull;&nbsp;<strong>إسهال:</strong>&nbsp;إذا كنت تعاني من زيادة 4 مرات أو أكثر في حركات الأمعاء مقارنة بحركات أمعائك الطبيعية كل يوم أو أي إسهال في الليل.</p><p dir="RTL">&bull;&nbsp;<strong>قيء:</strong>&nbsp;إذا تقيأت أكثر من مرة واحدة خلال فترة 24 ساعة.</p><p dir="RTL">&bull;&nbsp;<strong>غثيان:</strong>&nbsp;إذا فقدت شهيتك، وإذا كانت كمية الطعام التي تتناولها كل يوم أقل بكثير من المعتاد.</p><p dir="RTL">&bull;&nbsp;<strong>التهاب فم:</strong>&nbsp;إذا حصل عندك ألم, احمرار, تورم أو تقرحات في فمك و/أو حلقك.</p><p dir="RTL">&bull;&nbsp;<strong>رد فعل في جلد اليد والقدم:</strong>&nbsp;إذا حصل عندك ألم, أو تورم, احمرار أو وخز في اليدين و/أو القدمين.</p><p dir="RTL">&bull;&nbsp;<strong>حمى:</strong>&nbsp;إذا حصل عندك درجة حرارة 38&deg; مئوية أو أكثر.</p><p dir="RTL">&bull;&nbsp;<strong>عدوى:</strong>&nbsp;إذا كنت تعاني من علامات عدوى سببها البكتيريا أو الفيروسات, أو كائنات حية أخرى.</p><p dir="RTL">&bull;&nbsp;<strong>ألم في الصدر:</strong>&nbsp;إذا كنت تعاني من ألم متوضع في مركز الصدر، خاصةً إذا كان يحدث أثناء التمرين.</p><p dir="RTL">&bull;&nbsp;<strong>متلازمة ستيفن - جونسون:</strong>&nbsp;إذا كنت تعاني من طفح جلدي مؤلم أحمر أو أرجواني منتشر وبثور و/أو آفات أخرى بدأت تظهر في الغشاء المخاطي (مثل الفم والشفاه)، وبخاصة إذا كنت قد تعرضت من قبل لحساسية الضوء، التهابات الجهاز التنفسي (مثل التهاب الشعب الهوائية) و/أو الحمى.</p><p dir="RTL">&bull;&nbsp;<strong>نقص&nbsp;</strong><strong>DPD</strong><strong>:</strong>&nbsp;إذا كان لديك نقصاً معروفاً في&nbsp;DPD, فأنت أكثر عرضة لخطر السمية المبكرة والتفاعلات الضارة الشديدة التي تهدد الحياة أو المميتة الناجمة عن&nbsp;<strong>إمكاب</strong>&nbsp;(مثل التهاب الفم، التهاب الغشاء المخاطي، إسهال، قلة العِدلات, والسمية العصبية).</p><p dir="RTL">إذا اكتُشفت باكراً, فإن هذه التأثيرات عادةً ما تتحسَّن في غضون يومين إلى ثلاثة أيام بعد وقف العلاج.</p><p dir="RTL">إذا استمرت هذه التأثيرات الجانبية، بكل الأحوال, اتصل بطبيبك على الفور. فقد يوصيك طبيبك بإعادة بدء المعالجة بجرعة أقل.</p><p dir="RTL">يمكن أن يؤدي رد فعل الجلد في اليد والقدم لفقدان بصمة الأصابع، مما قد يؤثر على هويتك في ماسحة بصمات الأصابع.</p><p dir="RTL">إضافة لما سبق، عند استخدام&nbsp;<strong>إمكاب</strong>&nbsp;بمفرده، فإن التأثيرات الجانبية الشائعة جداً, والتي قد تؤثر في أكثر من 1 من كل 10 أشخاص هي:</p><p dir="RTL">&bull; وجع بطن,</p><p dir="RTL">&bull; طفح, جفاف أو حكة جلدية,</p><p dir="RTL">&bull; تعب,</p><p dir="RTL">&bull; فقدان شهية (فقدان قابلية).</p><p dir="RTL">هذه التأثيرات الجانبية يمكن أن تصبح شديدة, لذا، من المهم&nbsp;<strong>الاتصال دائماً بطبيبك على الفور</strong>&nbsp;عندما تبدأ بالمعاناة من أي تأثير جانبي. قد يوصيك طبيبك بتخفيض الجرعة و/أو وقف العلاج مؤقتاً بدواء&nbsp;<strong>إمكاب</strong>. وسيساعد ذلك في تقليل احتمالية استمرار التأثير الجانبي أو يصبح شديداً.</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى هي:</strong></p><p dir="RTL">التأثيرات الجانبية الشائعة (قد تؤثر حتى في 1 من كل 10 أشخاص) وهي تشمل:</p><p dir="RTL">&bull; انخفاض في عدد خلايا الدم البيضاء أو خلايا الدم الحمراء (تظهر في الفحوصات),</p><p dir="RTL">&bull; جفاف، فقدان وزن,</p><p dir="RTL">&bull; أرق (الأرق) واكتئاب,</p><p dir="RTL">&bull; صداع، نعاس، دوار، إحساس غير طبيعي في الجلد (خدر أو تنميل خفيف)، تغيرات في التذوق,</p><p dir="RTL">&bull; تهيج العين، دموع زائدة، احمرار العين (التهاب الملتحمة),</p><p dir="RTL">&bull; التهاب الأوردة (التهاب الوريد الخثاري),</p><p dir="RTL">&bull; ضيق تنفس، نزيف أنف، سعال، سيلان أنف,</p><p dir="RTL">&bull; قروح باردة أو التهابات هربس أخرى,</p><p dir="RTL">&bull; عدوى الرئتين أو الجهاز التنفسي (مثل التهاب الرئة أو التهاب الشعب الهوائية),</p><p dir="RTL">&bull; نزيف من الأمعاء, إمساك, آلم في أعلى البطن, عسر هضم, ريح زائدة, جفاف فم,</p><p dir="RTL">&bull; طفح جلدي، تساقط شعر (ثعلبة)، احمرار جلد، جلد جاف، حكة (الحكة)، تلون الجلد، فقدان الجلد، التهاب الجلد، اضطراب الأظافر,</p><p dir="RTL">&bull; ألم في المفاصل, أو في الأطراف (أطراف الجسم) الصدر أو الظهر,</p><p dir="RTL">&bull; حمى، تورم في الأطراف، شعور بالمرض,</p><p dir="RTL">&bull; مشاكل في وظائف الكبد (تظهر في فحوصات الدم) وزيادة في بيليروبين الدم (المطروح بواسطة الكبد).</p><p dir="RTL">التأثيرات الجانبية غير الشائعة (قد تؤثر حتى في 1 من كل 100 شخص) وهي تشمل:</p><p dir="RTL">&bull; عدوى الدم، التهاب المسالك البولية، التهاب الجلد، التهابات في الأنف والحلق، التهابات فطرية (بما فيها الخاصة بالفم)، أنفلونزا، التهاب المعدة والأمعاء، خراج الأسنان,</p><p dir="RTL">&bull; كتل تحت الجلد (ورم شحمي),</p><p dir="RTL">&bull; انخفاض خلايا الدم بما فيها الصفيحات الدموية، تميُّع الدم (تظهر في الفحوصات),</p><p dir="RTL">&bull; حساسية,</p><p dir="RTL">&bull; مرض السكري، نقص بوتاسيوم الدم، سوء تغذية، زيادة الدهون الثلاثية في الدم,</p><p dir="RTL">&bull; حالة ارتباك، نوبات هلع، مزاج مكتئب، انخفاض الرغبة الجنسية,</p><p dir="RTL">&bull; صعوبة في التكلم, ضعف ذاكرة, فقدان تنسيق الحركة,&nbsp;&nbsp;اضطراب التوازن, إغماء, تلف أعصاب (اعتلال الأعصاب) ومشاكل في الإحساس,</p><p dir="RTL">&bull; عدم وضوح أو إزدواجية الرؤية,</p><p dir="RTL">&bull; الدوار، ألم الأذن,</p><p dir="RTL">&bull; عدم انتظام ضربات القلب والخفقان (عدم انتظام ضربات القلب)، ألم في الصدر ونوبة قلبية (احتشاء),</p><p dir="RTL">&bull; جلطات دموية في الأوردة العميقة، ضغط دم مرتفع أو منخفض، هبّات ساخنة، أطراف باردة (الأطراف) ، بقع أرجوانية على الجلد,</p><p dir="RTL">&bull; جلطات دموية في أوردة الرئة (انسداد رئوي)، رئة متهدمة، سعال دموي، ربو، ضيق تنفس عند الجُهد,</p><p dir="RTL">&bull; انسداد الأمعاء، تجمُّع السوائل&nbsp;&nbsp;في البطن، التهاب الأمعاء الدقيقة أو الغليظة، المعدة أو المريء، ألم أسفل البطن، عدم راحة البطن، حرقة (حرقة ارتداد الطعام من المعدة)، دم في البراز,</p><p dir="RTL">&bull; يرقان (اصفرار الجلد والعينين),</p><p dir="RTL">&bull; قرحة جلد وبثور, رد فعل الجلد من أشعة الشمس، احمرار باطن الكفّين، تورم أو ألم في الوجه,</p><p dir="RTL">&bull; تورم أو تصلب المفاصل، ألم العظام، ضعف أو تصلُّب العضلات,</p><p dir="RTL">&bull; تجمُّع السوائل في الكلى، زيادة مرات التبول أثناء الليل، سلس بولي، دم في البول، زيادة كرياتينين الدم (علامة اختلال وظائف الكلى),</p><p dir="RTL">&bull; نزيف غير عادي من المهبل,</p><p dir="RTL">&bull; تورم (وذمة)، قشعريرة وقساوة.</p><p dir="RTL">بعض هذه التأثيرات الجانبية هي أكثر شيوعاً عند استخدام دواء كابيسيتابين مع أدوية أخرى لعلاج السرطان. التأثيرات الجانبية الأخرى الظاهرة في هذا الوضع هي التالية:</p><p dir="RTL">التأثيرات الجانبية الشائعة (قد تؤثر حتى في 1 من كل 10 أشخاص) وهي تشمل:</p><p dir="RTL">&bull; انخفاض صوديوم الدم, المغنيسيوم أو الكالسيوم، زيادة في سكر الدم,</p><p dir="RTL">&bull; ألم أعصاب,</p><p dir="RTL">&bull; رنين أو طنين في الأذنين (طنين)، فقدان السمع,</p><p dir="RTL">&bull; التهاب وريدي,</p><p dir="RTL">&bull; فُواق، تغيُّر في الصوت,</p><p dir="RTL">&bull; ألم أو تغيُّر غير طبيعي بالإحساس في الفم، ألم في الفك,</p><p dir="RTL">&bull; تعرُّق، تعرُّق في الليل,</p><p dir="RTL">&bull; تشنج العضلات,</p><p dir="RTL">&bull; صعوبة في التبول, دم أو بروتين في البول,</p><p dir="RTL">&bull; كدمات أو رد فعل في مكان الحقن (بسبب الأدوية التي تعطى عن طريق الحقن بنفس الوقت).</p><p dir="RTL">التأثيرات الجانبية النادرة (قد تؤثر حتى في 1 من كل 1000 شخص) وهي تشمل:</p><p dir="RTL">&bull; تضيُّق أو انسداد قناة الدمع (تضيق القناة الدمعية),</p><p dir="RTL">&bull; فشل كبدى,</p><p dir="RTL">&bull; التهاب يؤدي لخلل وظيفي أو انسداد في إفراز الصفراء (التهاب الكبد الصفراوي),</p><p dir="RTL">&bull; تغيُّرات نوعية في تخطيط القلب الكهربائي (إطالة زمن الـ&nbsp;QT),</p><p dir="RTL">&bull; أنواع معينة من عدم انتظام ضربات القلب (بما في ذلك رجفان بطيني، نوع معين من إيقاع القلب غير طبيعي&nbsp;TdP&nbsp;يمكن أن يؤدي للموت، وبطء القلب),</p><p dir="RTL">&bull; التهاب العين المسبب لألم العين وربما في مشاكل الرؤية,</p><p dir="RTL">&bull; التهاب الجلد المسبب لانتشار بقع حمراء بسبب مرض الجهاز المناعي.</p><p dir="RTL">التأثيرات الجانبية النادرة جداً (قد تؤثر حتى في 1 من كل 10000 شخص) وهي تشمل:</p><p dir="RTL">&bull; رد فعل جلدي شديد مثل الطفح الجلدي، تقرُّح وبثور قد تشمل تقرحات في الفم, الأنف, الأعضاء التناسلية, اليدين, القدمين والعينين (عيون حمراء ومنتفخة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تحفظه بدرجة حرارة فوق 30&ordm; مئوية. واحفظه من الضوء.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية واللصاقة بعد&nbsp;EXP. ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تُساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي كابيسيتابين. كل قرص مغلف بفيلم يحتوي على 500 ملغ من كابيسيتابين.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL"><em>قلب القرص:</em>&nbsp;مايكرو كريستالين السَّلولوز (PH 101)، لاكتوز لامائي، كروسكاميلوز الصوديوم، هايدروكسي بروبيل ميثيل السَّلولوز، ستيرات المغنيسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غلاف القرص:</em>&nbsp;طلاء بني كامل نوع&nbsp;03A565005&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص بلون الخوخ الخفيف إلى لون الخوخ، مستطيلة الشكل محدبة الجانبين مغلفة بفيلم، محفورة بالحرف &quot;C&quot; على جانب واحد والرقم &quot;500&quot; على الجانب الآخر. كل 10 أقراص من&nbsp;<strong>إمكاب</strong>&nbsp;معبأة في عبوة بليستر ألمنيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة تداوي الطبية الحيوية،</p><p dir="RTL">منطقة سُدير الصناعية,</p><p dir="RTL">سُدير،</p><p dir="RTL">المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             07/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EMCAP 500
Capecitabine Tablets USP 500 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 500 mg of capecitabine 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Light peach to peach colored, oblong shaped biconvex film coated tablets, debossed with “C” on one side and “500” on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EMCAP is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of:</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->for the adjuvant treatment of patients following surgery of stage iii (dukes&#39; stage c) colon cancer (see section 5.1).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->metastatic&nbsp;colorectal&nbsp;cancer (see&nbsp;section&nbsp;5.1).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->first-line treatment of advanced gastric cancer in combination with a platinum-based regimen (see section 5.1).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.</p><p>as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EMCAP should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic medicinal products. Careful monitoring during the first cycle of treatment is recommended for all patients.</p><p>Treatment should be discontinued if progressive disease or intolerable toxicity is observed. Standard and reduced dose calculations according to body surface area for starting doses of EMCAP of&nbsp;1250 mg/m<sup>2</sup>&nbsp;and 1000 mg/m<sup>2</sup>&nbsp;are provided in tables 1 and 2, respectively.</p><p><u>Posology</u></p><p>Recommended&nbsp;posology&nbsp;(see&nbsp;section&nbsp;5.1)</p><p>&nbsp;</p><p><u>Monotherapy</u></p><p><em>Colon,&nbsp;colorectal&nbsp;and&nbsp;breast&nbsp;cancer</em></p><p>Given as monotherapy, the recommended starting dose for capecitabine in the adjuvant treatment of colon cancer, in the treatment of metastatic colorectal cancer or of locally advanced or metastatic breast cancer is 1250 mg/m<sup>2</sup>&nbsp;administered twice daily (morning and evening; equivalent to 2500 mg/m<sup>2</sup>&nbsp;total daily dose) for 14 days followed by a 7-day rest period. Adjuvant treatment in patients with stage III colon cancer is recommended for atotal of 6 months.</p><p>&nbsp;</p><p><u>Combination&nbsp;therapy</u></p><p><em>Colon,&nbsp;colorectal&nbsp;and&nbsp;gastric&nbsp;cancer</em></p><p>In combination treatment, the recommended starting dose of capecitabine should be reduced to&nbsp;800&nbsp;-1000&nbsp;mg/m<sup>2</sup>&nbsp;whenadministered&nbsp;twice&nbsp;daily&nbsp;for&nbsp;14&nbsp;days&nbsp;followed&nbsp;by&nbsp;a&nbsp;7-day&nbsp;rest&nbsp;period, or to 625 mg/m<sup>2</sup>&nbsp;twice daily when administered continuously (see section 5.1). For combination&nbsp;with&nbsp;irinotecan,&nbsp;the&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;is&nbsp;800&nbsp;mg/m<sup>2</sup>&nbsp;when&nbsp;administered twice daily for 14 days followed by&nbsp;a 7-day&nbsp;rest period combined with irinotecan&nbsp;200 mg/m<sup>2</sup>&nbsp;on&nbsp;day&nbsp;1.&nbsp;The&nbsp;inclusion&nbsp;of&nbsp;bevacizumab&nbsp;in&nbsp;acombination&nbsp;regimen&nbsp;has&nbsp;no&nbsp;effect&nbsp;on&nbsp;the&nbsp;starting dose&nbsp;of&nbsp;capecitabine.&nbsp;Premedication&nbsp;to&nbsp;maintain&nbsp;adequate&nbsp;hydration&nbsp;and&nbsp;anti-emesis&nbsp;according to the cisplatin summary of product characteristics should be started prior to cisplatin administration for patients receiving the capecitabine plus cisplatin combination. Premedication with antiemetics according to the oxaliplatin summary of product characteristics is recommended for patients receiving the capecitabine plus oxaliplatin combination.&nbsp;Adjuvant treatmentin&nbsp;patients&nbsp;with&nbsp;stage&nbsp;III&nbsp;colon&nbsp;cancer is&nbsp;recommended for&nbsp;a duration of 6 months.</p><p><u>Breast&nbsp;cancer</u></p><p>In&nbsp;combination&nbsp;with&nbsp;docetaxel,&nbsp;the&nbsp;recommended&nbsp;starting&nbsp;dose&nbsp;of&nbsp;capecitabine&nbsp;in&nbsp;the&nbsp;treatment of metastatic breast cancer is 1250 mg/m<sup>2</sup>&nbsp;twice daily for 14 days followed by a 7- day rest period, combined with&nbsp;docetaxelat 75&nbsp;mg/m<sup>2</sup>&nbsp;as&nbsp;a&nbsp;1&nbsp;hour intravenous infusion&nbsp;every&nbsp;3&nbsp;weeks. Premedication with an oral corticosteroid such as dexamethasone according to the docetaxel summary of product characteristics should be started prior to docetaxel administration for patients receiving the capecitabine plus docetaxel combination.</p><p>&nbsp;</p><p><u>EMCAP&nbsp;dose&nbsp;calculations</u></p><p>Table 1. Standard and reduced dose calculations&nbsp;according to body&nbsp;surface area for a starting dose of capecitabine of 1250 mg/m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>Dose&nbsp;level&nbsp;1250&nbsp;mg/m<sup>2</sup>&nbsp;(twice&nbsp;daily)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Full dose 1250&nbsp;mg/m<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>Number of 150 mg tablets and/or 500 mg tablets&nbsp;per&nbsp;administration</p><p>(each&nbsp;administration&nbsp;to&nbsp;be&nbsp;given morning and evening)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Reduced&nbsp;dose(75%)</p><p>950&nbsp;mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Reduced&nbsp;dose&nbsp;(50%)</p><p>625&nbsp;mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Body&nbsp;Surface Area (m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose per&nbsp;administration</p><p>(mg)</p></td><td style="vertical-align:top"><p>150&nbsp;mg</p></td><td style="vertical-align:top"><p>500&nbsp;mg</p></td><td style="vertical-align:top"><p>Dose per&nbsp;administration</p><p>(mg)</p></td><td style="vertical-align:top"><p>Dose per&nbsp;administration</p><p>(mg)</p></td></tr><tr><td style="vertical-align:top"><p>&le;1.26</p></td><td style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1150</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.27&nbsp;-&nbsp;1.38</p></td><td style="vertical-align:top"><p>1650</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.39&nbsp;-&nbsp;1.52</p></td><td style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1450</p></td><td style="vertical-align:top"><p>950</p></td></tr><tr><td style="vertical-align:top"><p>1.53&nbsp;-&nbsp;1.66</p></td><td style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>1000</p></td></tr><tr><td style="vertical-align:top"><p>1.67&nbsp;-&nbsp;1.78</p></td><td style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1650</p></td><td style="vertical-align:top"><p>1000</p></td></tr><tr><td style="vertical-align:top"><p>1.79&nbsp;-&nbsp;1.92</p></td><td style="vertical-align:top"><p>2300</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>1150</p></td></tr><tr><td style="vertical-align:top"><p>1.93&nbsp;-&nbsp;2.06</p></td><td style="vertical-align:top"><p>2500</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1950</p></td><td style="vertical-align:top"><p>1300</p></td></tr><tr><td style="vertical-align:top"><p>2.07&nbsp;-&nbsp;2.18</p></td><td style="vertical-align:top"><p>2650</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>1300</p></td></tr><tr><td style="vertical-align:top"><p>&ge;2.19</p></td><td style="vertical-align:top"><p>2800</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1450</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 2. Standard and reduced dose calculations&nbsp;according to body&nbsp;surface area for a starting dose of EMCAP of 1000 mg/m<sup>2</sup></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>Dose&nbsp;level&nbsp;1000&nbsp;mg/m<sup>2</sup>&nbsp;(twice&nbsp;daily)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Full dose 1000&nbsp;mg/m<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>Number of 150 mg tablets and/or 500 mg tablets&nbsp;per&nbsp;administration</p><p>(each&nbsp;administration&nbsp;to&nbsp;be&nbsp;given morning and evening)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Reduced&nbsp;dose&nbsp;(75%)</p><p>750&nbsp;mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Reduced&nbsp;dose&nbsp;(50%)</p><p>500&nbsp;mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Body&nbsp;Surface Area (m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose per&nbsp;administration</p><p>(mg)</p></td><td style="vertical-align:top"><p>150&nbsp;mg</p></td><td style="vertical-align:top"><p>500&nbsp;mg</p></td><td style="vertical-align:top"><p>Dose per&nbsp;administration</p><p>(mg)</p></td><td style="vertical-align:top"><p>Dose per&nbsp;administration</p><p>(mg)</p></td></tr><tr><td style="vertical-align:top"><p>&le;1.26</p></td><td style="vertical-align:top"><p>1150</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>800</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>1.27&nbsp;-&nbsp;1.38</p></td><td style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1000</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>1.39&nbsp;-&nbsp;1.52</p></td><td style="vertical-align:top"><p>1450</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1100</p></td><td style="vertical-align:top"><p>750</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1025px"><tbody><tr><td style="vertical-align:top; width:152px"><p>1.53&nbsp;-&nbsp;1.66</p></td><td style="vertical-align:top; width:156px"><p>1600</p></td><td style="vertical-align:top; width:197px"><p>4</p></td><td style="vertical-align:top; width:205px"><p>2</p></td><td style="vertical-align:top; width:155px"><p>1200</p></td><td style="vertical-align:top; width:159px"><p>800</p></td></tr><tr><td style="vertical-align:top; width:152px"><p>1.67&nbsp;-&nbsp;1.78</p></td><td style="vertical-align:top; width:156px"><p>1750</p></td><td style="vertical-align:top; width:197px"><p>5</p></td><td style="vertical-align:top; width:205px"><p>2</p></td><td style="vertical-align:top; width:155px"><p>1300</p></td><td style="vertical-align:top; width:159px"><p>800</p></td></tr><tr><td style="vertical-align:top; width:152px"><p>1.79&nbsp;-&nbsp;1.92</p></td><td style="vertical-align:top; width:156px"><p>1800</p></td><td style="vertical-align:top; width:197px"><p>2</p></td><td style="vertical-align:top; width:205px"><p>2</p></td><td style="vertical-align:top; width:155px"><p>1400</p></td><td style="vertical-align:top; width:159px"><p>900</p></td></tr><tr><td style="vertical-align:top; width:152px"><p>1.93&nbsp;-&nbsp;2.06</p></td><td style="vertical-align:top; width:156px"><p>2000</p></td><td style="vertical-align:top; width:197px"><p>-</p></td><td style="vertical-align:top; width:205px"><p>4</p></td><td style="vertical-align:top; width:155px"><p>1500</p></td><td style="vertical-align:top; width:159px"><p>1000</p></td></tr><tr><td style="vertical-align:top; width:152px"><p>2.07&nbsp;-&nbsp;2.18</p></td><td style="vertical-align:top; width:156px"><p>2150</p></td><td style="vertical-align:top; width:197px"><p>1</p></td><td style="vertical-align:top; width:205px"><p>4</p></td><td style="vertical-align:top; width:155px"><p>1600</p></td><td style="vertical-align:top; width:159px"><p>1050</p></td></tr><tr><td style="vertical-align:top; width:152px"><p>&ge;2.19</p></td><td style="vertical-align:top; width:156px"><p>2300</p></td><td style="vertical-align:top; width:197px"><p>2</p></td><td style="vertical-align:top; width:205px"><p>4</p></td><td style="vertical-align:top; width:155px"><p>1750</p></td><td style="vertical-align:top; width:159px"><p>1100</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Posology&nbsp;adjustments&nbsp;during&nbsp;treatment</u></em><em>&nbsp;General</em></p><p>Toxicity&nbsp;due&nbsp;to&nbsp;capecitabine&nbsp;administration&nbsp;may&nbsp;be&nbsp;managed&nbsp;by&nbsp;symptomatic&nbsp;treatment&nbsp;and/or modification of the dose (treatment interruption or dose reduction). Once the dose has been reduced,&nbsp;it&nbsp;should&nbsp;not&nbsp;be&nbsp;increased&nbsp;ata&nbsp;later&nbsp;time.&nbsp;For&nbsp;those&nbsp;toxicities&nbsp;considered&nbsp;by&nbsp;the&nbsp;treating physician&nbsp;to be&nbsp;unlikely&nbsp;to become&nbsp;serious&nbsp;or life-threatening, e.g. alopecia, altered&nbsp;taste, nail changes, treatment can be continued at the same dose without reduction or interruption.</p><p>Patients&nbsp;taking&nbsp;capecitabine&nbsp;should&nbsp;be&nbsp;informed&nbsp;of&nbsp;the&nbsp;need&nbsp;to&nbsp;interrupt&nbsp;treatment&nbsp;immediately if moderate or severe toxicity occurs. Doses of capecitabine omitted for toxicity are not replaced. The following are the recommended dose modifications for toxicity:</p><p>Table&nbsp;3&nbsp;Capecitabine&nbsp;dose&nbsp;reduction&nbsp;schedule&nbsp;(3&nbsp;weekly&nbsp;cycle&nbsp;or&nbsp;continuous&nbsp;treatment)</p><table border="1" cellspacing="0" cellpadding="0" style="width:816px"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity&nbsp;grades*</strong></p></td><td style="vertical-align:top"><p><strong>Dose&nbsp;changes&nbsp;within&nbsp;a&nbsp;treatment&nbsp;cycle</strong></p></td><td style="vertical-align:top; width:414px"><p><strong>Dose adjustment for next cycle/dose&nbsp;(%&nbsp;of&nbsp;starting&nbsp;dose)</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;<!--[endif]-->Grade&nbsp;1</p></td><td style="vertical-align:top"><p>Maintain&nbsp;dose&nbsp;level</p></td><td style="vertical-align:top; width:414px"><p>Maintain&nbsp;dose&nbsp;level</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:813px"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;<!--[endif]-->Grade&nbsp;2</p></td></tr><tr><td style="vertical-align:top"><p>-1st&nbsp;appearance</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>Interrupt&nbsp;until&nbsp;resolved&nbsp;to&nbsp;grade&nbsp;0-1</p></td><td style="vertical-align:top; width:414px"><p>100%</p></td></tr><tr><td style="vertical-align:top"><p>-2nd&nbsp;appearance</p></td><td style="vertical-align:top; width:414px"><p>75%</p></td></tr><tr><td style="vertical-align:top"><p>-3rd&nbsp;appearance</p></td><td style="vertical-align:top; width:414px"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-4th&nbsp;appearance</p></td><td style="vertical-align:top"><p>Discontinue&nbsp;treatment&nbsp;permanently</p></td><td style="vertical-align:top; width:414px"><p>Not&nbsp;applicable</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:813px"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;<!--[endif]-->Grade&nbsp;3</p></td></tr><tr><td style="vertical-align:top"><p>-1st&nbsp;appearance</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Interrupt&nbsp;until&nbsp;resolved&nbsp;to&nbsp;grade&nbsp;0-1</p></td><td style="vertical-align:top; width:414px"><p>75%</p></td></tr><tr><td style="vertical-align:top"><p>-2nd&nbsp;appearance</p></td><td style="vertical-align:top; width:414px"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-3rd&nbsp;appearance</p></td><td style="vertical-align:top"><p>Discontinue&nbsp;treatment&nbsp;permanently</p></td><td style="vertical-align:top; width:414px"><p>Not&nbsp;applicable</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:813px"><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;<!--[endif]-->Grade&nbsp;4</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>-1st&nbsp;appearance</p></td><td style="vertical-align:top"><p>Discontinue&nbsp;permanently&nbsp;or</p><p>If&nbsp;physician&nbsp;deems&nbsp;it&nbsp;to&nbsp;be&nbsp;in&nbsp;thepatient&#39;s best interest to continue, interrupt until resolved to grade 0-1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-2nd&nbsp;appearance</p></td><td style="vertical-align:top"><p>Discontinue&nbsp;permanently</p></td><td style="vertical-align:top"><p>Not&nbsp;applicable</p></td></tr></tbody></table><p>&nbsp;</p><p>*According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity&nbsp;Criteria(version&nbsp;1)&nbsp;or&nbsp;the&nbsp;Common&nbsp;Terminology&nbsp;Criteria&nbsp;for&nbsp;Adverse&nbsp;Events&nbsp;(CTCAE)&nbsp;of&nbsp;the Cancer Therapy Evaluation Program, US National Cancer Institute, version 4.0. For hand-foot syndrome and hyperbilirubinemia, see section 4.4.</p><p>&nbsp;</p><p><strong><em>Haematology</em></strong></p><p>Patients&nbsp;with&nbsp;baseline&nbsp;neutrophil&nbsp;counts&nbsp;of&nbsp;&lt;1.5x10<sup>9</sup>/L&nbsp;and/or&nbsp;thrombocyte&nbsp;counts&nbsp;of</p><p>&lt;100x10<sup>9</sup>/L should not be treated with capecitabine. If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 10<sup>9</sup>/L or that the platelet count drops below 75 x 10<sup>9</sup>/L, treatment with capecitabine should be interrupted.</p><p><em>Dose modifications&nbsp;for toxicity when capecitabine is used as&nbsp;a 3&nbsp;weekly cycle in combination with other medicinal products</em></p><p>Dose&nbsp;modifications for&nbsp;toxicity&nbsp;when&nbsp;capecitabine is&nbsp;used&nbsp;as&nbsp;a&nbsp;3&nbsp;weekly&nbsp;cycle in&nbsp;combination with&nbsp;othermedicinal&nbsp;products&nbsp;should&nbsp;be&nbsp;made&nbsp;according&nbsp;to&nbsp;table&nbsp;3&nbsp;above&nbsp;for&nbsp;capecitabine&nbsp;and according to the appropriate summary of product characteristics for the other medicinal&nbsp;product(s).</p><p>At the beginning of&nbsp;a treatment cycle, if&nbsp;a treatment delay&nbsp;is indicated for either capecitabine or the other medicinal product(s), then administration of all therapy should be delayed until the requirements for restarting all medicinal products are met.</p><p>During a treatment cycle for those toxicities considered by the treating physician not to be related to capecitabine, capecitabine should be continued and the dose of&nbsp;the other medicinal product should be adjusted according to the appropriate Prescribing Information.</p><p>If&nbsp;the&nbsp;other medicinal&nbsp;product(s)&nbsp;have&nbsp;to be&nbsp;discontinued&nbsp;permanently,&nbsp;capecitabine&nbsp;treatment can be resumed when the requirements for restarting capecitabine are met.</p><p>This&nbsp;advice&nbsp;is&nbsp;applicable&nbsp;to&nbsp;all&nbsp;indications&nbsp;and&nbsp;to&nbsp;all&nbsp;special&nbsp;populations.</p><p>&nbsp;</p><p><em>Dose modifications for toxicity when capecitabine is used continuously in combination with other medicinal products</em></p><p>&nbsp;</p><p>Dose modifications for toxicity when capecitabine is used continuously in combination with other medicinal products should be made according to table 3 above for capecitabine and according to the appropriate summary of product characteristics for the other medicinal&nbsp;product(s).</p><p>&nbsp;</p><p><u>Posology&nbsp;adjustments for&nbsp;special&nbsp;populations:</u></p><p><u>Hepatic&nbsp;impairment</u></p><p>Insufficient safety and efficacy data are available in patients with hepatic impairment to&nbsp;provide&nbsp;a&nbsp;doseadjustment recommendation.&nbsp;No information is&nbsp;available&nbsp;on&nbsp;hepatic impairment&nbsp;due to cirrhosis or hepatitis.</p><p><u>Renal&nbsp;impairment</u></p><p>Capecitabine is&nbsp;contraindicated in&nbsp;patients&nbsp;with&nbsp;severe&nbsp;renal&nbsp;impairment (creatinine&nbsp;clearance below 30 ml/min [Cockcroft and Gault] at baseline). The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min at baseline) is increased compared to the overall population. In patients with moderate renal impairment at baseline, a dose reduction to 75% for a starting dose of 1250 mg/m<sup>2</sup>&nbsp;is recommended. In patients with moderate renal impairment at baseline, no dose reduction is required for&nbsp;a&nbsp;starting&nbsp;dose&nbsp;of&nbsp;1000 mg/m<sup>2</sup>.&nbsp;In&nbsp;patients&nbsp;with&nbsp;mild&nbsp;renal impairment (creatinine clearance 51-80 ml/min at baseline) no adjustment of the starting dose is recommended.</p><p>Careful&nbsp;monitoring&nbsp;and&nbsp;prompt&nbsp;treatment interruption&nbsp;is&nbsp;recommended&nbsp;if&nbsp;the&nbsp;patient develops a&nbsp;grade&nbsp;2,&nbsp;3&nbsp;or&nbsp;4adverse&nbsp;event&nbsp;during&nbsp;treatment&nbsp;and&nbsp;subsequent&nbsp;dose&nbsp;adjustment&nbsp;as&nbsp;outlined&nbsp;in table&nbsp;3&nbsp;above.&nbsp;If&nbsp;the&nbsp;calculatedcreatinine&nbsp;clearance&nbsp;decreases&nbsp;during&nbsp;treatment&nbsp;to&nbsp;a&nbsp;value&nbsp;below 30&nbsp;ml/min,&nbsp;Capecitabine&nbsp;should&nbsp;be&nbsp;discontinued.These&nbsp;dose&nbsp;adjustment&nbsp;recommendations&nbsp;for renal&nbsp;impairment apply both&nbsp;to monotherapy&nbsp;and combination&nbsp;use (see also section&nbsp;&ldquo;Elderly&rdquo;&nbsp;below).</p><p><u>Elderly</u></p><p>During capecitabine monotherapy, no adjustment of the starting dose is needed. However, grade 3 or 4 treatment-related adverse reactions were more frequent in patients &ge;60 years of age compared to younger patients.</p><p>When capecitabine was used in combination with other medicinal products, elderly patients (&ge;65&nbsp;years)experienced&nbsp;more&nbsp;grade&nbsp;3&nbsp;and&nbsp;grade&nbsp;4&nbsp;adverse&nbsp;drug&nbsp;reactions,&nbsp;including&nbsp;those leading to discontinuation, compared to younger patients. Careful monitoring of&nbsp;patients &ge;60 years of age is advisable.</p><p>-&nbsp;<em>In combination with docetaxel:&nbsp;</em>an increased incidence of grade 3 or 4 treatment-related adverse&nbsp;reactions&nbsp;andtreatment-related&nbsp;serious&nbsp;adverse&nbsp;reactions&nbsp;were&nbsp;observed in&nbsp;patients 60 years of age or more (see section 5.1). For patients 60 years of age or more, a starting dose reduction of capecitabine to 75% (950 mg/m<sup>2</sup>&nbsp;twice daily) is recommended. If no toxicity is observed in patients &ge;60 years of&nbsp;age treated with&nbsp;reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m<sup>2</sup>&nbsp;twice daily.</p><p><u>Paediatric&nbsp;population</u></p><p>There is&nbsp;no relevant use&nbsp;of&nbsp;capecitabine in&nbsp;the&nbsp;paediatric&nbsp;population&nbsp;in&nbsp;the indications&nbsp;colon, colorectal, gastric and breast cancer.</p><p><u>Method&nbsp;of&nbsp;administration</u></p><p>EMCAP&nbsp;should&nbsp;be&nbsp;swallowed&nbsp;whole&nbsp;with&nbsp;water&nbsp;within&nbsp;30&nbsp;minutes&nbsp;after&nbsp;a&nbsp;meal.&nbsp;EMCAP should not be crushed or cut.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	History of severe and unexpected reactions to fluoropyrimidine therapy,
•	Hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil,
•	In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity (see section 4.4),
•	During pregnancy and lactation,
•	In patients with severe leukopenia, neutropenia, or thrombocytopenia,
•	In patients with severe hepatic impairment,
•	In patients with severe renal impairment (creatinine clearance below 30 ml/min),
•	Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug interaction),
•	If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dose&nbsp;limiting&nbsp;toxicities</u></p><p><u>Dose limiting toxicities</u>&nbsp;include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome&nbsp;(hand-foot&nbsp;skin&nbsp;reaction,&nbsp;palmar-plantar&nbsp;erythrodysesthesia).&nbsp;Most&nbsp;adverse&nbsp;reactions are reversible and do not require permanent discontinuation of therapy, although doses may need to be withheld or reduced.</p><p><em><u>Diarrhoea</u></em><u>.</u></p><p>&nbsp;Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. Standard antidiarrhoeal treatments (e.g. loperamide) may be used. NCIC CTC grade 2 diarrhoea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhoea as an increase of 7 to 9 stools/day or incontinence&nbsp;and malabsorption.&nbsp;Grade 4&nbsp;diarrhoea&nbsp;is&nbsp;an&nbsp;increase&nbsp;of&nbsp;&ge;10stools/day&nbsp;or&nbsp;grossly bloody diarrhoea or the need for parenteral support. Dose reduction should be applied as necessary (see section 4.2).</p><p><em><u>Dehydration.</u></em></p><p><em>&nbsp;</em>Dehydration should be prevented or corrected at the onset. Patients with anorexia, asthenia, nausea, vomiting or diarrhoea may rapidly become dehydrated. Dehydration may cause acute renal failure, especially in patients with pre-existing compromised renal function or when capecitabine is given concomitantly with known nephrotoxic medicinal products. Acute renal failure secondary to dehydration might be potentially fatal. If grade 2 (or higher) dehydration occurs, capecitabine treatment should be immediately&nbsp;interrupted&nbsp;and&nbsp;thedehydration&nbsp;corrected.&nbsp;Treatment&nbsp;should&nbsp;not&nbsp;be&nbsp;restarted&nbsp;until the&nbsp;patient is&nbsp;rehydrated&nbsp;and&nbsp;any&nbsp;precipitatingcauses have been corrected&nbsp;or controlled. Dose modifications applied should be applied for the precipitating adverse event as necessary&nbsp;(see section 4.2).</p><p><em><u>Hand-foot syndrome</u>&nbsp;</em></p><p>(also known as hand-foot skin reaction or palmar-plantar erythrodysesthesia or chemotherapy&nbsp;induced acral&nbsp;erythema). Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient&#39;s normal activities. Grade 2&nbsp;hand-foot syndrome is&nbsp;painful&nbsp;erythema and swelling ofthe hands&nbsp;and/or&nbsp;feet and/or discomfort affecting the patient&#39;s activities of daily living. Grade 3 hand-foot syndrome is moist desquamation, ulceration, blistering and severe pain of the hands and/or feet and/or severediscomfort&nbsp;that&nbsp;causes&nbsp;the&nbsp;patient&nbsp;to&nbsp;be&nbsp;unable&nbsp;to&nbsp;work&nbsp;or&nbsp;perform&nbsp;activities&nbsp;of&nbsp;daily&nbsp;living. Persistent or severe hand-foot syndrome (Grade 2 and above) can eventually lead to loss of fingerprints which could impact patient identification.</p><p>If&nbsp;grade&nbsp;2&nbsp;or&nbsp;3&nbsp;hand-foot&nbsp;syndrome&nbsp;occurs,&nbsp;administration&nbsp;of&nbsp;capecitabine&nbsp;should&nbsp;be&nbsp;interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-foot syndrome, subsequent doses of capecitabine should be decreased. When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand&ndash;foot syndrome, because of published reports that it may decrease the efficacy of cisplatin. There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with&nbsp;Capecitabine.</p><p><em><u>Cardiotoxicity.</u>&nbsp;</em></p><p>Cardiotoxicity has been associated with fluoropyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death and electrocardiographic changes (including very rare cases of QT prolongation). These adverse reactions may be more common in patients with a prior history of coronary artery disease. Cardiac arrhythmias (including ventricular fibrillation, torsade de pointes, and bradycardia), angina pectoris, myocardial infarction, heart failure and cardiomyopathy have been reported in patients receiving capecitabine. Caution must be exercised in patients with history of significant cardiac disease, arrhythmias and angina pectoris (see section 4.8).</p><p><em><u>Hypo- or hypercalcaemia</u></em>.</p><p>Hypo- or hypercalcaemia has been reported during capecitabine treatment. Caution must be exercised in patients with pre-existing hypo- or hypercalcaemia (see section 4.8).</p><p><em><u>Central or peripheral nervous system disease</u></em><em>.&nbsp;</em></p><p>Caution must be exercised in patients with central or peripheral nervous system disease, e.g. brain metastasis or neuropathy (see section&nbsp;4.8).</p><p><em><u>Diabetes mellitus or electrolyte disturbances</u></em>.</p><p>Caution must be exercised in patients with diabetes mellitus or electrolyte disturbances, as&nbsp;these may be aggravated during capecitabine&nbsp;treatment.</p><p><em><u>Coumarin-derivative anticoagulation</u></em><u>.</u>&nbsp;</p><p>In an interaction study with single-dose warfarin administration,&nbsp;therewas&nbsp;a&nbsp;significant&nbsp;increase&nbsp;in&nbsp;the&nbsp;mean&nbsp;AUC&nbsp;(+57%)&nbsp;of&nbsp;S-warfarin.&nbsp;These results suggest an interaction, probably due to an inhibition of the cytochrome P450 2C9 isoenzyme&nbsp;system&nbsp;by&nbsp;capecitabine.&nbsp;Patients&nbsp;receivingconcomitant&nbsp;capecitabine&nbsp;and&nbsp;oral&nbsp;coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5).</p><p><em><u>Brivudine.</u>&nbsp;</em></p><p>Brivudine must not be administered concomitantly with capecitabine. Fatal cases have been reported following this drug interaction. There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy. Treatment with brivudine can be started 24 hours after the last dose of&nbsp;capecitabine (see section 4.3 and 4.5). In the event of accidental administration of brivudine to patients being treated with capecitabine, effective measures should be taken to reduce the toxicity of capecitabine. Immediateadmission&nbsp;to hospital&nbsp;is&nbsp;recommended.&nbsp;All&nbsp;measures&nbsp;should&nbsp;be initiated&nbsp;to prevent systemic infections and dehydration.</p><p><em><u>Hepatic impairment.</u>&nbsp;</em></p><p>In the absence of safety and efficacy data in patients with hepatic impairment,Capecitabine&nbsp;use&nbsp;should&nbsp;be&nbsp;carefully&nbsp;monitored&nbsp;in&nbsp;patients&nbsp;with&nbsp;mild&nbsp;to&nbsp;moderate liver dysfunction, regardless ofthe presence or absence of&nbsp;liver metastasis. Administration&nbsp;of capecitabine should be interrupted if treatment-related elevations in bilirubin of &gt;3.0 x ULN or&nbsp;treatment-related&nbsp;elevations&nbsp;in&nbsp;hepatic&nbsp;aminotransferases&nbsp;(ALT,AST)&nbsp;of&nbsp;&gt;2.5&nbsp;x&nbsp;ULN&nbsp;occur. Treatment&nbsp;with&nbsp;capecitabine&nbsp;monotherapy&nbsp;may&nbsp;be&nbsp;resumed&nbsp;when&nbsp;bilirubin&nbsp;decreasesto&nbsp;&le;3.0&nbsp;x ULN or hepatic aminotransferases decrease to &le; 2.5 x ULN.</p><p><em><u>Renal impairment</u></em>.</p><p>The incidence of grade 3&nbsp;or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).</p><p><em><u>Dihydropyrimidine&nbsp;dehydrogenase&nbsp;(DPD)&nbsp;deficiency:</u></em><em>&nbsp;</em></p><p>Rarely,&nbsp;unexpected,&nbsp;severe&nbsp;toxicity&nbsp;(e.g. stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-FU has been attributed to a deficiency of DPD activity.</p><p>Patients&nbsp;with&nbsp;low&nbsp;or&nbsp;absent DPD&nbsp;activity, an&nbsp;enzyme&nbsp;involved&nbsp;in&nbsp;fluorouracil&nbsp;degradation,&nbsp;are at increased risk for severe, life-threatening, or fatal&nbsp;adverse reactions&nbsp;caused by&nbsp;fluorouracil. Although DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the DPYD gene locus (e.g. DPYD*2A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3 variants), which can cause complete&nbsp;or&nbsp;near&nbsp;complete&nbsp;absence&nbsp;of&nbsp;DPD&nbsp;enzymatic&nbsp;activity&nbsp;(as&nbsp;determined&nbsp;from&nbsp;laboratory assays),&nbsp;have&nbsp;the&nbsp;highest&nbsp;risk&nbsp;of&nbsp;life-threatening&nbsp;or&nbsp;fatal&nbsp;toxicity&nbsp;and&nbsp;should&nbsp;not&nbsp;be&nbsp;treated&nbsp;with&nbsp;Capecitabine (see section 4.3). No dose has been proven safe for patients with complete absence of DPD activity.</p><p>Patients with certain heterozygous DPYD variants (including DPYD*2A, c.1679T&gt;G, c.2846A&gt;T&nbsp;andc.1236G&gt;A/HapB3&nbsp;variants)&nbsp;have&nbsp;been&nbsp;shown&nbsp;to&nbsp;have&nbsp;increased&nbsp;risk&nbsp;of&nbsp;severe toxicity when treated with capecitabine.</p><p>The frequency of the heterozygous DPYD*2A genotype in the DPYD gene in Caucasian patients&nbsp;is&nbsp;around&nbsp;1%,1.1%&nbsp;for&nbsp;c.2846A&gt;T,&nbsp;2.6-6.3%&nbsp;for&nbsp;c.1236G&gt;A/HapB3&nbsp;variants&nbsp;and</p><p>0.07&nbsp;to&nbsp;0.1%&nbsp;for&nbsp;c.1679T&gt;G.&nbsp;Genotyping&nbsp;for&nbsp;these&nbsp;alleles&nbsp;is&nbsp;recommended&nbsp;to&nbsp;identify&nbsp;patients at increased risk for severe toxicity. Data on the frequency of these DPYD variants in other populations&nbsp;than&nbsp;Caucasian is limited. It cannot be excluded that other rare variants may&nbsp;also be associated with an increased risk of severe toxicity.</p><p>For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of Capecitabine are considered to outweigh the risks (taking into account the suitability of an alternative nonfluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjustment according to toxicity. A reduction of the starting dose in these patients may be&nbsp;considered&nbsp;to&nbsp;avoid&nbsp;serious&nbsp;toxicity.&nbsp;There&nbsp;is&nbsp;insufficient&nbsp;data&nbsp;to&nbsp;recommend&nbsp;a&nbsp;specific&nbsp;dose inpatients&nbsp;with&nbsp;partial&nbsp;DPD&nbsp;activity&nbsp;as measured by&nbsp;specific test.&nbsp;It has&nbsp;been&nbsp;reported&nbsp;that&nbsp;the DPYD*2A,c.1679T&gt;G&nbsp;variants&nbsp;lead&nbsp;to&nbsp;a&nbsp;greater&nbsp;reduction&nbsp;in&nbsp;enzymatic&nbsp;activity&nbsp;than&nbsp;the&nbsp;other variants&nbsp;with&nbsp;a&nbsp;higher&nbsp;risk&nbsp;ofside&nbsp;effects.&nbsp;The&nbsp;consequences&nbsp;of&nbsp;a&nbsp;reduced&nbsp;dose&nbsp;for&nbsp;efficacy&nbsp;are currently uncertain. Therefore, in the absence of serious toxicity the dose could be increased while carefully monitoring the patient.</p><p>The patients who are tested negative for the above-mentioned alleles may still have a risk of severe adverse events.</p><p>In patients with unrecognised DPD deficiency treated with capecitabine as well as in those patients&nbsp;who&nbsp;testnegative&nbsp;for&nbsp;specific&nbsp;DPYD&nbsp;variations,&nbsp;life-threatening&nbsp;toxicities&nbsp;manifesting as acute overdose may occur (see section 4.9). In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately.</p><p>Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities.</p><p><em><u>Ophthalmologic&nbsp;complications</u></em>:&nbsp;</p><p>Patients&nbsp;should&nbsp;be&nbsp;carefully&nbsp;monitored&nbsp;for&nbsp;ophthalmological&nbsp;</p><p>complications&nbsp;such&nbsp;as&nbsp;keratitis&nbsp;and&nbsp;corneal&nbsp;disorders, especially&nbsp;if&nbsp;they&nbsp;have&nbsp;a&nbsp;prior history&nbsp;of eye disorders. Treatment of eye disorders should be initiated as clinically appropriate.</p><p><em><u>Severe&nbsp;skin&nbsp;reactions:</u>&nbsp;</em></p><p>Capecitabine&nbsp;can&nbsp;induce&nbsp;severe&nbsp;skin&nbsp;reactions&nbsp;such&nbsp;as&nbsp;Stevens-Johnson syndrome&nbsp;andToxic&nbsp;Epidermal&nbsp;Necrolysis.&nbsp;Capecitabine&nbsp;should&nbsp;be&nbsp;permanently&nbsp;discontinued in patients who experience a severe skin reaction during treatment.</p><p>As this medicinal product contains anhydrous lactose as an excipient, patients with rare hereditary&nbsp;problems&nbsp;ofgalactose&nbsp;intolerance,&nbsp;the&nbsp;Lapp&nbsp;lactase&nbsp;deficiency&nbsp;or&nbsp;glucose-galactose malabsorption should not take this medicine.</p><p>EMCAP should not be crushed or cut. In case of exposure of either patient or caregiver to crushed or cut EMCAP tablets adverse drug reactions could occur (see Section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction&nbsp;studies&nbsp;have&nbsp;only&nbsp;been&nbsp;performed&nbsp;in&nbsp;adults.&nbsp;<u>Interaction with other medicinal products</u></p><p><em>Brivudine:&nbsp;</em>a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-Fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described. This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, brivudine must not be administered concomitantly with capecitabine (see section 4.3 and 4.4). There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy. Treatment with brivudine can be started 24 hours after the last dose of capecitabine.</p><p><em>Cytochrome&nbsp;P-450&nbsp;2C9&nbsp;substrates:&nbsp;</em>Other&nbsp;than&nbsp;warfarin,&nbsp;no&nbsp;formal&nbsp;interaction&nbsp;studies&nbsp;between capecitabine and other CYP2C9 substrates have been conducted. Care should be exercised when capecitabine is co-administered with 2C9 substrates (e.g., phenytoin). See also interaction with coumarin-derivative anticoagulants below, and section 4.4.</p><p><em>Coumarin-derivative anticoagulants:&nbsp;</em>altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants&nbsp;such&nbsp;as&nbsp;warfarin&nbsp;andphenprocoumon. These reactions&nbsp;occurred&nbsp;within&nbsp;several days&nbsp;and up&nbsp;to several&nbsp;months&nbsp;after initiating capecitabine therapy&nbsp;and, in&nbsp;a few cases, within one month&nbsp;after stopping capecitabine. In&nbsp;a&nbsp;clinicalpharmacokinetic interaction&nbsp;study, after&nbsp;a single&nbsp;20&nbsp;mg&nbsp;dose&nbsp;of&nbsp;warfarin,&nbsp;capecitabine&nbsp;treatment&nbsp;increased&nbsp;theAUC&nbsp;of&nbsp;S-warfarin&nbsp;by&nbsp;57%&nbsp;with&nbsp;a&nbsp;91%&nbsp;increase&nbsp;in&nbsp;INR&nbsp;value.&nbsp;Since&nbsp;metabolism&nbsp;of&nbsp;R-warfarin&nbsp;was&nbsp;not&nbsp;affected,&nbsp;these results indicatethat capecitabine&nbsp;down-regulates&nbsp;isozyme 2C9, but has&nbsp;no effect on&nbsp;isozymes 1A2 and 3A4. Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine&nbsp;should&nbsp;be&nbsp;monitored&nbsp;regularly&nbsp;foralterations&nbsp;in&nbsp;their&nbsp;coagulation&nbsp;parameters&nbsp;(PT or INR) and the anticoagulant dose adjusted accordingly.</p><p><em>Phenytoin:&nbsp;</em>increased phenytoin plasma concentrations resulting in symptoms of phenytoin intoxication in single cases have been reported during concomitant use of capecitabine with phenytoin. Patients taking phenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.</p><p><em><u>Folinic acid/folic acid</u>:&nbsp;</em>a combination study&nbsp;with capecitabine and folinic acid indicated that folinic acid has no major effect on the pharmacokinetics of capecitabine and its metabolites. However, folinic acid has an&nbsp;effect onthe pharmacodynamics of&nbsp;capecitabine and its toxicity may be enhanced by folinic acid: the maximum tolerated dose (MTD) of capecitabine alone using the intermittent regimen is 3000 mg/m<sup>2</sup>&nbsp;per day&nbsp;whereas it is only&nbsp;2000 mg/m<sup>2</sup>&nbsp;per day when capecitabine was combined with folinic acid (30 mg orally bid). The enhanced toxicity may be relevant when switching from&nbsp;5- FU/LV to a&nbsp;capecitabine regimen. This may&nbsp;also be relevant with folic acid supplementation for folate deficiency due to the similarity between folinic acid and folic acid.</p><p><em><u>Antacid:</u>&nbsp;</em>the effect of&nbsp;an aluminium hydroxide and magnesium hydroxide-containing antacid on the pharmacokinetics of capecitabine was investigated. There was a small increase in plasma concentrations ofcapecitabine and one metabolite (5&#39;-DFCR); there was no effect on the 3 major metabolites (5&#39;-DFUR, 5-FU and FBAL).</p><p><em><u>Allopurinol</u></em>: interactions with allopurinol have been observed for 5-FU; with possible decreased efficacy of 5-FU. Concomitant use of allopurinol with capecitabine should be&nbsp;avoided.</p><p><em><u>Interferon alpha:</u>&nbsp;</em>the MTD of capecitabine was 2000 mg/m2 per day when combined with interferon&nbsp;alpha-2a (3 MIU/m<sup>2</sup>&nbsp;per day) compared to 3000&nbsp;mg/m2 per day&nbsp;when&nbsp;capecitabine was used alone.</p><p><em><u>Radiotherapy:</u>&nbsp;</em>the MTD of&nbsp;capecitabine alone using the intermittent regimen is 3000 mg/m2 per&nbsp;day,&nbsp;whereas,when&nbsp;combined&nbsp;with&nbsp;radiotherapy&nbsp;for&nbsp;rectal&nbsp;cancer,&nbsp;the&nbsp;MTD&nbsp;of&nbsp;capecitabine &nbsp;is 2000 mg/m<sup>2</sup>&nbsp;per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.</p><p><em><u>Oxaliplatin</u></em>:&nbsp;no&nbsp;clinically&nbsp;significant&nbsp;differences&nbsp;in&nbsp;exposure&nbsp;to&nbsp;capecitabine&nbsp;or&nbsp;its&nbsp;metabolites, free platinum or total platinum&nbsp;occurred when capecitabine was administered in combination with oxaliplatin or in combination with oxaliplatin and bevacizumab.</p><p><em><u>Bevacizumab:</u>&nbsp;</em>there&nbsp;was&nbsp;no clinically&nbsp;significant effect of&nbsp;bevacizumab&nbsp;on&nbsp;the&nbsp;pharmacokinetic&nbsp;parameters of capecitabine or its metabolites in the presence of oxaliplatin.</p><p>&nbsp;</p><p><u>Food&nbsp;interaction</u></p><p>In&nbsp;all&nbsp;clinical&nbsp;trials,&nbsp;patients&nbsp;were&nbsp;instructed&nbsp;to&nbsp;administer&nbsp;capecitabine&nbsp;within&nbsp;30&nbsp;minutes&nbsp;after a meal. Since current safety and efficacy data are based upon administration with food, it is recommended that capecitabine be administered with food. Administration with food decreases the rate of capecitabine absorption (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women&nbsp;of&nbsp;childbearing&nbsp;potential/Contraception&nbsp;in&nbsp;males&nbsp;and&nbsp;females</u></p><p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with capecitabine. If the patient becomes pregnant while receiving capecitabine, the potential hazard to the foetus must be explained. An effective method of contraception should be used during treatment and for 6&nbsp;months after the last dose of&nbsp;capecitabine.</p><p>Based&nbsp;on&nbsp;genetic&nbsp;toxicity&nbsp;findings,&nbsp;male&nbsp;patients&nbsp;with&nbsp;female&nbsp;partners&nbsp;of&nbsp;reproductive&nbsp;potential should use effective contraception during treatment and for 3 months following the last dose of capecitabine.</p><p><u>Pregnancy</u></p><p>There are no studies in pregnant women using capecitabine; however, it should be assumed that capecitabine may cause foetal harm if administered to pregnant women. In reproductive toxicity studies in animals, capecitabine administration caused embryolethality and teratogenicity. These findings are expected effects of fluoropyrimidine derivatives. Capecitabine is contraindicated during pregnancy.</p><p><u>Breast-feeding</u></p><p>It is not known whether capecitabine is excreted in human breast milk. No studies have been conducted to assess the impact of capecitabine on milk production or its presence in human breast milk. In lactating mice, considerable amounts&nbsp;of&nbsp;capecitabine and its metabolites were found&nbsp;in&nbsp;milk.&nbsp;As&nbsp;the&nbsp;potential&nbsp;for&nbsp;harm&nbsp;to&nbsp;thenursing&nbsp;infant&nbsp;is&nbsp;unknown,&nbsp;breast-feeding&nbsp;should be discontinued while receiving treatment with capecitabine and for 2&nbsp;weeks after the final&nbsp;dose.</p><p><u>Fertility</u></p><p>There is no data on capecitabine and impact on fertility. The capecitabine pivotal studies included females ofchildbearing potential and males only if they&nbsp;agreed to use an&nbsp;acceptable method of birth control&nbsp;to avoid pregnancy for the duration of&nbsp;the study&nbsp;and for a reasonable period thereafter.</p><p>In&nbsp;animal&nbsp;studies&nbsp;effects&nbsp;on&nbsp;fertility&nbsp;were&nbsp;observed&nbsp;(see&nbsp;section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine has minor or moderate influence on the ability to drive and use machines.</p><p>Capecitabine may cause dizziness, fatigue and nausea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary&nbsp;of&nbsp;the&nbsp;safety&nbsp;profile</u></p><p>The&nbsp;overall&nbsp;safety&nbsp;profile&nbsp;of&nbsp;capecitabine&nbsp;is&nbsp;based&nbsp;on&nbsp;data&nbsp;from&nbsp;over&nbsp;3000&nbsp;patients&nbsp;treated&nbsp;with capecitabine as monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications. The safety profiles of capecitabine monotherapy for the metastatic breast cancer, metastatic colorectal cancer and adjuvant colon cancer populations are&nbsp;comparable.&nbsp;See&nbsp;section&nbsp;5.1&nbsp;for&nbsp;details&nbsp;of&nbsp;major&nbsp;studies,&nbsp;including&nbsp;studydesigns&nbsp;and&nbsp;major efficacy results.</p><p>The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal&nbsp;pain,&nbsp;stomatitis),&nbsp;hand-footsyndrome&nbsp;(palmar-plantar&nbsp;erythrodysesthesia),&nbsp;fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/embolism.</p><p><u>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions</u></p><p>ADRs considered by the investigator to be possibly, probably, or remotely related to the administration&nbsp;ofcapecitabine are listed in&nbsp;table&nbsp;4 for capecitabine&nbsp;given&nbsp;as monotherapy&nbsp;and in table 5 for capecitabine given in combination with different chemotherapy regimens in multiple indications. The following headings are used to rank the ADRs by frequency: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt;1/1,000), very rare (&lt; 1/10,000). Within each frequency grouping, ADRs are presented in order of decreasing seriousness.</p><p><em><u>Capecitabine&nbsp;Monotherapy:</u></em></p><p>Table 4 lists ADRs associated with the use of capecitabine monotherapy based on a pooled analysis&nbsp;of&nbsp;safetydata&nbsp;from&nbsp;three&nbsp;major&nbsp;studies&nbsp;including&nbsp;over&nbsp;1900&nbsp;patients&nbsp;(studies&nbsp;M66001, SO14695,&nbsp;and&nbsp;SO14796).&nbsp;ADRs&nbsp;areadded&nbsp;to&nbsp;the&nbsp;appropriate&nbsp;frequency&nbsp;grouping&nbsp;according&nbsp;to the overall incidence from the pooled analysis.</p><p>Table&nbsp;4&nbsp;Summary&nbsp;of&nbsp;related&nbsp;ADRs&nbsp;reported&nbsp;in&nbsp;patients&nbsp;treated&nbsp;with&nbsp;capecitabine&nbsp;monotherapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body&nbsp;System</strong></p></td><td style="vertical-align:top"><p><strong>Very&nbsp;Common&nbsp;All&nbsp;grades</strong></p></td><td style="vertical-align:top"><p><strong>Common&nbsp;All&nbsp;grades</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon&nbsp;Severe&nbsp;and/or&nbsp;Life</strong></p><p><strong>threatening&nbsp;(grade&nbsp;3-4)&nbsp;orconsidered medically</strong></p><p><strong>relevant</strong></p></td><td style="vertical-align:top"><p><strong>Rare/Very&nbsp;Rare&nbsp;(Post-Marketing Experience)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections&nbsp;and&nbsp;infestations</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Herpes viral&nbsp;infection, Nasopharyngitis,&nbsp;Lowerrespiratory tract infection</p></td><td style="vertical-align:top"><p>Sepsis, Urinary tract infection, Cellulitis,&nbsp;Tonsillitis,&nbsp;Pharyngitis, Oral&nbsp;candidiasis,Influenza, Gastroenteritis, Fungalinfection, Infection,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tooth</p><p>abscess</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Neoplasm benign,</em></p><p><em>malignant&nbsp;and&nbsp;unspecified</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Lipoma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood&nbsp;and&nbsp;lymphatic system</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Neutropenia, Anaemia</p></td><td style="vertical-align:top"><p>Febrileneutropenia,&nbsp;Pancytopenia, Granulocytopenia,</p><p>Thrombocytopenia,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia, Haemolyticanaemia, International&nbsp;Normalised Ratio&nbsp;(INR)</p><p>increased/Prothrombi&nbsp;n time prolonged</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune&nbsp;system&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism&nbsp;and&nbsp;nutrition disorders</em></p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Dehydration, Weight decreased</p></td><td style="vertical-align:top"><p>Diabetes, Hypokalaemia,&nbsp;Appetite disorder,&nbsp;Malnutrition,</p><p>Hypertriglyceridaemi&nbsp;a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Insomnia, Depression</p></td><td style="vertical-align:top"><p>Confusionalstate, Panic attack, Depressed mood,</p><p>Libido&nbsp;decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous&nbsp;system&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Headache, Lethargy Dizziness, Parasthesia Dysgeusia</p></td><td style="vertical-align:top"><p>Aphasia, Memory impairment,Ataxia, Syncope, Balance disorder, Sensory&nbsp;disorder, Neuropathy</p><p>peripheral</p></td><td style="vertical-align:top"><p>Toxic leukoencephalopath&nbsp;y</p><p>(very&nbsp;rare)</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Lacrimation increased,&nbsp;Conjunctivitis,Eye&nbsp;irritation</p></td><td style="vertical-align:top"><p>Visual&nbsp;acuity&nbsp;reduced, Diplopia</p></td><td style="vertical-align:top"><p>Lacrimal duct stenosis (rare),&nbsp;Corneal disorders(rare),&nbsp;keratitis (rare), punctatekeratitis</p><p>(rare)</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear and&nbsp;labyrinth</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Vertigo,&nbsp;Ear&nbsp;pain</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Angina unstable, Angina pectoris,&nbsp;Myocardial ischaemia/infarction,&nbsp;Atrial fibrillation,&nbsp;Arrhythmia,&nbsp;Tachycardia, Sinus&nbsp;tachycardia,</p><p>Palpitations</p></td><td style="vertical-align:top"><p>Ventricular&nbsp;fibrillation (rare), QT prolongation (rare), Torsade de pointes (rare), Bradycardia(rare), Vasospasm (rare)</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p></td><td style="vertical-align:top"><p>Deep vein&nbsp;thrombosis,</p><p>Hypertension, Petechiae,</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension,&nbsp;Hot&nbsp;flush, Peripheral</p><p>coldness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory,&nbsp;thoracic&nbsp;and&nbsp;mediastinal disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Dyspnoea, Epistaxis, Cough, Rhinorrhoea</p></td><td style="vertical-align:top"><p>Pulmonary embolism, Pneumothorax, Haemoptysis, Asthma,</p><p>Dyspnoea&nbsp;exertional</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestina&nbsp;l disorder</em></p></td><td style="vertical-align:top"><p>Diarrhoea, Vomiting, Nausea, Stomatitis, Abdominal&nbsp;pain</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage, Constipation,&nbsp;Upperabdominal&nbsp;pain,</p><p>Dyspepsia,&nbsp;Flatulence,Dry&nbsp;mouth</p></td><td style="vertical-align:top"><p>Intestinalobstruction,&nbsp;Ascites,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enteritis,&nbsp;Gastritis,&nbsp;Dysphagia, Abdominal pain lower, Oesophagitis,&nbsp;Abdominal discomfort, Gastrooesophageal</p><p>reflux&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disease,&nbsp;Colitis,&nbsp;Blood&nbsp;in&nbsp;stool</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorder</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperbilirubinemi&nbsp;a, Liver function test abnormalities</p></td><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>Hepatic&nbsp;failure&nbsp;(rare)</p><p>Cholestatic&nbsp;hepatitis</p><p>(rare)</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorder</em></p></td><td style="vertical-align:top"><p>Palmar- plantar Erythro- dysaesthesi&nbsp;a&nbsp;syndrome*</p><p>*</p></td><td style="vertical-align:top"><p>Rash, Alopecia, Erythema, Dry skin,&nbsp;Pruritus,&nbsp;Skin&nbsp;hyperpigmentation,Rash&nbsp;macular,&nbsp;Skin&nbsp;desquamation, Dermatitis, Pigmentation&nbsp;disorder, Nail</p><p>disorder</p></td><td style="vertical-align:top"><p>Blister,&nbsp;Skin&nbsp;ulcer,&nbsp;Rash,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Urticaria, Photosensitivity reaction,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Palmar erythema,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Swelling face,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpura, Radiation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recall syndrome</p></td><td style="vertical-align:top"><p>Cutaneous lupuserythematosus&nbsp;(rare), Severe skin reactions such as&nbsp;Stevens-Johnson&nbsp;Syndrome&nbsp;andtoxic&nbsp;Epidermal&nbsp;Necrolysis (very rare) (see section</p><p>4.4.)</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeleta&nbsp;l and&nbsp;connective</em></p><p><em>tissue disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Pain&nbsp;in&nbsp;extremity, Back pain,&nbsp;Arthralgia</p></td><td style="vertical-align:top"><p>Joint&nbsp;swelling,&nbsp;Bone pain, Facial pain,&nbsp;Musculoskeletal</p><p>stiffness,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Muscular weakness</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal&nbsp;and&nbsp;urinary disorder</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hydronephrosis,&nbsp;Urinaryincontinence,&nbsp;Haematuria,Nocturia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Blood</p><p>creatinine&nbsp;increased</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive&nbsp;system and&nbsp;breast</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Vaginal&nbsp;haemorrhage</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p><em>General&nbsp;disorders&nbsp;and</em></p></td><td style="vertical-align:top"><p>Fatigue, Asthenia</p></td><td style="vertical-align:top"><p>Pyrexia,&nbsp;Oedema peripheral,</p></td><td style="vertical-align:top"><p>Oedema,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;chills,&nbsp;Influenza&nbsp;likeillness,</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1397px"><tbody><tr><td style="vertical-align:top; width:126px"><p><em>administration&nbsp;site&nbsp;conditions</em></p></td><td style="vertical-align:top; width:150px"><p>&nbsp;</p></td><td style="vertical-align:top; width:359px"><p>Malaise,&nbsp;Chestpain</p></td><td style="vertical-align:top; width:379px"><p>Rigors,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Body&nbsp;temperatureincreased</p></td><td style="vertical-align:top; width:382px"><p>&nbsp;</p></td></tr></tbody></table><p>** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysaesthesia syndrome can eventually lead to loss of fingerprints (see section 4.4)</p><p>&nbsp;</p><p><em><u>Capecitabine&nbsp;in combination&nbsp;therapy</u></em></p><p>Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapyregimens in multiple indications based on&nbsp;safety&nbsp;data from&nbsp;over 3000 patients. ADRs&nbsp;are&nbsp;added&nbsp;to&nbsp;theappropriate&nbsp;frequency&nbsp;grouping&nbsp;(Very&nbsp;common&nbsp;or&nbsp;Common)&nbsp;according to&nbsp;the&nbsp;highest incidence&nbsp;seen&nbsp;in&nbsp;any&nbsp;of&nbsp;themajor&nbsp;clinical&nbsp;trials&nbsp;and&nbsp;are&nbsp;only&nbsp;added&nbsp;when&nbsp;they were seen in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy (see table 4). Uncommon ADRs reported for capecitabine in combination therapy are consistent with the ADRs reported for capecitabine monotherapy or reported for monotherapy with the combination medicinal product (in literature and/or respective summary of product characteristics).</p><p>Some&nbsp;of&nbsp;the&nbsp;ADRs&nbsp;are&nbsp;reactions&nbsp;commonly&nbsp;seen&nbsp;with&nbsp;the&nbsp;combination&nbsp;medicinal&nbsp;product&nbsp;(e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy cannot be excluded.</p><p>Table 5. Summary of related ADRs reported in patients treated with capecitabine in combination treatment in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy</p><table border="1" cellspacing="0" cellpadding="0" style="width:1398px"><tbody><tr><td style="vertical-align:top; width:154px"><p>&nbsp;</p><p><strong>Body&nbsp;System</strong></p></td><td style="vertical-align:top; width:316px"><p><strong>Very&nbsp;common</strong></p><p><strong><em>All&nbsp;grades</em></strong></p></td><td style="vertical-align:top; width:766px"><p><strong>Common</strong></p><p><strong><em>All&nbsp;grades</em></strong></p></td><td style="vertical-align:top; width:161px"><p><strong>Rare/Very Rare&nbsp;(Post-Marketing</strong></p><p><strong>Experience)</strong></p></td></tr><tr><td style="vertical-align:top; width:154px"><p>&nbsp;</p><p><em>Infections&nbsp;and&nbsp;infestations</em></p></td><td style="vertical-align:top; width:316px"><p>&nbsp;</p><p>&nbsp;</p><p>-</p></td><td style="vertical-align:top; width:766px"><p>Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection ,</p><p>Rhinitis,&nbsp;Influenza,&nbsp;+Infection, Oral herpes</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:154px"><p>&nbsp;</p><p>&nbsp;</p><p><em>Blood and lymphatic system&nbsp;disorders</em></p></td><td style="vertical-align:top; width:316px"><p>+Neutropenia,</p><p>+Leucopenia,</p><p>+Anaemia,</p><p>+Neutropenic&nbsp;fever,</p><p>Thrombocytopenia</p></td><td style="vertical-align:top; width:766px"><p>&nbsp;</p><p>Bone marrow depression,&nbsp;+Febrile&nbsp;Neutropenia</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:154px"><p><em>Immune&nbsp;system</em></p><p><em>disorders</em></p></td><td style="vertical-align:top; width:316px"><p>-</p></td><td style="vertical-align:top; width:766px"><p>Hypersensitivity</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Appetite&nbsp;decreased</p></td><td style="vertical-align:top"><p>Hypokalaemia,&nbsp;Hyponatraemia,Hypomagnesaemia,</p><p>Hypocalcaemia,&nbsp;Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Sleep&nbsp;disorder,&nbsp;Anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><em>Nervous&nbsp;system&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>Paraesthesia, Dysaesthesia,&nbsp;Peripheralneuropathy, Peripheral sensory&nbsp;neuropathy,</p><p>Dysgeusia,&nbsp;Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Neurotoxicity,&nbsp;Tremor,&nbsp;Neuralgia,&nbsp;Hypersensitivity&nbsp;reaction,&nbsp;Hypoaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><em>Eye&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Lacrimation&nbsp;increased</p></td><td style="vertical-align:top"><p>Visual&nbsp;disorders,&nbsp;Dry&nbsp;eye,&nbsp;Eye</p><p>pain, Visual&nbsp;impairment, Vision&nbsp;blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear&nbsp;and&nbsp;labyrinth</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Tinnitus,&nbsp;Hypoacusis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Atrial&nbsp;fibrillation, Cardiac&nbsp;ischaemia/infarction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>Lower&nbsp;limb&nbsp;oedema,&nbsp;Hypertension,</p><p>+Embolism&nbsp;and</p><p>thrombosis</p></td><td style="vertical-align:top"><p>Flushing,&nbsp;Hypotension, Hypertensive&nbsp;crisis, Hot flush,&nbsp;Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory,&nbsp;thoracic</em></p><p><em>and&nbsp;mediastinal system&nbsp;disorders</em></p></td><td style="vertical-align:top"><p>Sore throat, Dysaesthesia&nbsp;pharynx</p></td><td style="vertical-align:top"><p>Hiccups, Pharyngolaryngeal pain,&nbsp;Dysphonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>Constipation, Dyspepsia</p></td><td style="vertical-align:top"><p>Upper&nbsp;gastrointestinal haemorrhage,&nbsp;Mouth ulceration, Gastritis,&nbsp;Abdominal distension, Gastroesophageal reflux&nbsp;disease, Oral pain, Dysphagia, Rectal haemorrhage,&nbsp;Abdominal pain lower, Oral dysaesthesia,</p><p>Paraesthesia&nbsp;oral,&nbsp;Hypoaesthesia oral, Abdominal discomfort</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hepatic&nbsp;function&nbsp;abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous&nbsp;tissue</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>Alopecia,&nbsp;Nail&nbsp;disorder</p></td><td style="vertical-align:top"><p>Hyperhidrosis,&nbsp;Rash erythematous, Urticaria, Night sweats</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal&nbsp;and connective&nbsp;tissue</em></p><p><em>disorders</em></p></td><td style="vertical-align:top"><p>Myalgia,&nbsp;Arthralgia, Pain in extremity</p></td><td style="vertical-align:top"><p>Pain in jaw&nbsp;, Muscle&nbsp;spasms, Trismus,&nbsp;Muscular&nbsp;weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and&nbsp;urinary&nbsp;disorder</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Haematuria,&nbsp;Proteinuria, Creatinine&nbsp;renal&nbsp;clearance decreased, Dysuria</p></td><td style="vertical-align:top"><p>Acute&nbsp;&nbsp;renal&nbsp;&nbsp;failure</p><p>secondary&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;dehydration (rare)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:152px"><p><em>General disorders andadministration site conditions</em></p></td><td style="vertical-align:top; width:316px"><p>Pyrexia,&nbsp;Weakness,</p><p>+Lethargy, Temperature intolerance</p></td><td style="vertical-align:top; width:767px"><p>Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza- like illness,&nbsp;+Fever, Infusion&nbsp;related reaction, Injection site reaction, Infusion site pain,</p><p>Injection&nbsp;site&nbsp;pain</p></td><td style="vertical-align:top; width:159px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:152px"><p><em>Injury,&nbsp;poisoning&nbsp;and&nbsp;procedural</em></p><p><em>complications</em></p></td><td style="vertical-align:top; width:316px"><p>-</p></td><td style="vertical-align:top; width:767px"><p>Contusion</p></td><td style="vertical-align:top; width:159px"><p>&nbsp;</p></td></tr></tbody></table><p>+&nbsp;For each&nbsp;term, the&nbsp;frequency&nbsp;count was based&nbsp;on&nbsp;ADRs of&nbsp;all&nbsp;grades. For terms marked with&nbsp;a &ldquo;+&rdquo;, the&nbsp;frequencycount&nbsp;was&nbsp;based&nbsp;on&nbsp;grade&nbsp;3-4&nbsp;ADRs.&nbsp;ADRs&nbsp;are&nbsp;added&nbsp;according&nbsp;to&nbsp;the&nbsp;highest&nbsp;incidence seen in any of the major combination trials.</p><p>&nbsp;</p><p><u>Description&nbsp;of&nbsp;selected&nbsp;adverse&nbsp;reactions</u></p><p><em><u>Hand-foot&nbsp;syndrome&nbsp;(see&nbsp;section&nbsp;4.4):</u></em></p><p>For the capecitabine dose of 1250 mg/m<sup>2</sup>&nbsp;twice daily on days 1 to 14 every 3 weeks, a frequency&nbsp;of&nbsp;53%&nbsp;to 60%of&nbsp;all-grades HFS was observed in&nbsp;capecitabine monotherapy&nbsp;trials (comprising studies in adjuvant therapy in colon cancer, treatment of metastatic colorectal cancer, and treatment of breast cancer) and a frequency of 63% was observed in the capecitabine/docetaxel&nbsp;arm&nbsp;for&nbsp;the treatment of&nbsp;metastatic breast cancer. For&nbsp;the capecitabine dose&nbsp;of&nbsp;1000 mg/m<sup>2</sup>&nbsp;twice&nbsp;daily&nbsp;on&nbsp;days&nbsp;1&nbsp;to 14&nbsp;every&nbsp;3 weeks, a&nbsp;frequency&nbsp;of&nbsp;22%&nbsp;to 30%&nbsp;of all-grade HFS was observed in capecitabine combination therapy.</p><p>A&nbsp;meta-analysis&nbsp;of&nbsp;14&nbsp;clinical&nbsp;trials&nbsp;with&nbsp;data&nbsp;from&nbsp;over&nbsp;4700&nbsp;patients&nbsp;treated&nbsp;with&nbsp;capecitabine monotherapy&nbsp;orcapecitabine&nbsp;in&nbsp;combination&nbsp;with&nbsp;different&nbsp;chemotherapy&nbsp;regimens&nbsp;in&nbsp;multiple indications&nbsp;(colon,&nbsp;colorectal,gastric&nbsp;and&nbsp;breast&nbsp;cancer)&nbsp;showed&nbsp;that&nbsp;HFS&nbsp;(all&nbsp;grades)&nbsp;occurred in 2066 (43%) patients after a median time of 239 [95% CI 201, 288] days after starting treatment&nbsp;with&nbsp;capecitabine.&nbsp;In&nbsp;all&nbsp;studies&nbsp;combined,&nbsp;the&nbsp;followingcovariates&nbsp;were&nbsp;statistically significantly associated with an increased risk of developing HFS: increasing capecitabine starting dose (gram), decreasing cumulative capecitabine dose (0.1*kg), increasing relative doseintensity&nbsp;in&nbsp;the&nbsp;first&nbsp;six&nbsp;weeks,&nbsp;increasing&nbsp;duration&nbsp;of&nbsp;study&nbsp;treatment&nbsp;(weeks),&nbsp;increasing age (by 10 year increments), female gender, and good ECOG performance status at baseline (0 versus &ge;1).</p><p><em><u>Diarrhoea&nbsp;(see&nbsp;section&nbsp;4.4):</u></em></p><p>Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.</p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, the following covariates were statistically&nbsp;significantly&nbsp;associated&nbsp;with&nbsp;anincreased&nbsp;risk&nbsp;of&nbsp;developing&nbsp;diarrhoea:&nbsp;increasing capecitabine starting dose (gram), increasing duration of studytreatment (weeks), increasing age (by 10 year increments), and female gender. The following covariates were statistically significantly&nbsp;associated with a decreased risk of&nbsp;developing diarrhoea: increasing cumulative capecitabine dose (0.1*kg) and increasing relative dose intensity in the first six weeks.</p><p><em><u>Cardiotoxicity&nbsp;(see&nbsp;section&nbsp;4.4):</u></em></p><p>In&nbsp;addition&nbsp;to&nbsp;the&nbsp;ADRs&nbsp;described in&nbsp;tables&nbsp;4&nbsp;and 5,&nbsp;the&nbsp;following ADRs&nbsp;with&nbsp;an&nbsp;incidence&nbsp;of less than 0.1% were associated with the use of capecitabine monotherapy based on a pooled analysis from&nbsp;clinical safety&nbsp;data from&nbsp;7 clinical&nbsp;trials including 949 patients (2 phase III and</p><p>5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.</p><p><em><u>Encephalopathy:</u></em></p><p>In addition to the ADRs described in tables 4 and 5 and based on the above pooled analysis from&nbsp;clinical&nbsp;safetydata&nbsp;from&nbsp;7&nbsp;clinical&nbsp;trials,&nbsp;encephalopathy&nbsp;was&nbsp;also&nbsp;associated&nbsp;with&nbsp;the&nbsp;use of capecitabine monotherapy with an incidence of less than 0.1%.</p><p><em><u>Exposure&nbsp;to&nbsp;crushed&nbsp;or&nbsp;cut&nbsp;capecitabine&nbsp;tablets:</u></em></p><p>In the instance of&nbsp;exposure to crushed or cut capecitabine tablets, the following adverse drug reactions have been reported: eye irritation, eye swelling, skin rash, headache, paresthesia, diarrhea, nausea, gastric irritation, and vomiting.</p><p><em><u>Special&nbsp;populations</u></em></p><p><em><u>Elderly&nbsp;patients&nbsp;(see&nbsp;section&nbsp;4.2):</u></em></p><p>An&nbsp;analysis&nbsp;of&nbsp;safety&nbsp;data in&nbsp;patients&nbsp;&ge;60 years&nbsp;of&nbsp;age treated with&nbsp;capecitabine monotherapy and an analysis ofpatients treated with capecitabine plus docetaxel combination therapy showed an increase in&nbsp;the incidence oftreatment- related grade&nbsp;3 and 4&nbsp;adverse reactions and treatment-related&nbsp;serious&nbsp;adverse&nbsp;reactions&nbsp;compared&nbsp;topatients&nbsp;&lt;60&nbsp;years&nbsp;of&nbsp;age.&nbsp;</p><p>Patients&nbsp;&ge;60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients &lt;60 years of age.</p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with&nbsp;capecitabineshowed&nbsp;that&nbsp;in&nbsp;all&nbsp;studies&nbsp;combined, increasing&nbsp;age&nbsp;(by&nbsp;10&nbsp;year increments) was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.</p><p><em><u>Gender</u></em></p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, female gender was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.</p><p><em><u>Patients&nbsp;with&nbsp;renal&nbsp;impairment&nbsp;(see&nbsp;section&nbsp;4.2,&nbsp;4.4,&nbsp;and&nbsp;5.2):</u></em></p><p>An&nbsp;analysis&nbsp;of&nbsp;safety&nbsp;data&nbsp;in&nbsp;patients&nbsp;treated&nbsp;with&nbsp;capecitabine&nbsp;monotherapy&nbsp;(colorectal&nbsp;cancer) with&nbsp;baselinerenal&nbsp;impairment&nbsp;showed&nbsp;an&nbsp;increase in&nbsp;the&nbsp;incidence&nbsp;of&nbsp;treatment-related&nbsp;grade 3 and 4 adverse reactions compared to patients with normal renal function (36% in patients without renal impairment n=268, vs. 41% in mild n=257 and 54% in moderate n=59, respectively) (see section 5.2). Patients with moderately impaired renal function show an increased rate of dose reduction (44%) vs. 33% and 32% in patients with no or mild renal impairment and&nbsp;an&nbsp;increase in&nbsp;early&nbsp;withdrawals&nbsp;from&nbsp;treatment (21%&nbsp;withdrawals&nbsp;during&nbsp;the first two cycles) vs. 5% and 8% in patients with no or mild renal impairment.</p><p>Reporting&nbsp;of&nbsp;suspected&nbsp;adverse&nbsp;reactions</p><p><u>To&nbsp;reports&nbsp;any&nbsp;side&nbsp;effect(s):</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important.&nbsp;It&nbsp;allowscontinued&nbsp;monitoring&nbsp;of&nbsp;the&nbsp;benefit/risk&nbsp;balance&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product. Healthcare&nbsp;professionals&nbsp;are&nbsp;asked&nbsp;to report any&nbsp;suspected adverse&nbsp;reactions&nbsp;to&nbsp;the&nbsp;competent authority in Saudi Arabia as per details below:</p><p><!--[if !supportLists]--><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;National&nbsp;Pharmacovigilance&nbsp;and Drug&nbsp;Safety&nbsp;Centre&nbsp;(NPC)</strong></p><p><strong>o&nbsp;Fax: +966-11-205-7662</strong></p><p><strong>o&nbsp;Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222,&nbsp;Exts: 2317-2356-2353-2354-2334-2340.</strong></p><p><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;<!--[endif]-->Toll&nbsp;free&nbsp;phone:&nbsp;8002490000</strong></p><p><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;<!--[endif]-->E-mail:&nbsp;npc.drug@sfda.gov.sa</strong></p><p><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;<!--[endif]-->Website:&nbsp;www.sfda.gov.sa/npc</strong></p><p>To report the Adverse event in other GCC States - Please contact the relevant competent&nbsp;authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The manifestations of acute overdose include nausea, vomiting, diarrhoea, mucositis, gastrointestinal&nbsp;irritationand bleeding,&nbsp;and&nbsp;bone marrow&nbsp;depression.&nbsp;</p><p>Medical&nbsp;management&nbsp;of overdose&nbsp;should&nbsp;include&nbsp;customarytherapeutic&nbsp;and supportive&nbsp;medical&nbsp;interventions&nbsp;aimed&nbsp;at correcting the presenting clinical&nbsp;manifestations and preventing their possible complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;cytostatic&nbsp;(antimetabolite),&nbsp;ATC&nbsp;code:&nbsp;<em>L01BC06</em></p><p>Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administeredprecursor&nbsp;of&nbsp;the&nbsp;cytotoxic&nbsp;moiety&nbsp;5-fluorouracil&nbsp;(5-FU).&nbsp;Capecitabine&nbsp;is&nbsp;activated via several enzymatic steps (see section 5.2). The enzyme involved in the final conversion to 5-FU, thymidine phosphorylase (ThyPase), is found in tumour tissues, but also in normal tissues, albeit usually at lower levels. In human cancer xenograft models capecitabine demonstrated a synergistic effect in&nbsp;combination with&nbsp;docetaxel, which may&nbsp;be related to the upregulation of thymidine phosphorylase by docetaxel.</p><p>There&nbsp;is&nbsp;evidence&nbsp;that&nbsp;the&nbsp;metabolism&nbsp;of&nbsp;5-FU&nbsp;in&nbsp;the&nbsp;anabolic&nbsp;pathway&nbsp;blocks&nbsp;the&nbsp;methylation reaction of deoxyuridylic acid to thymidylic acid, thereby interfering with the synthesis of deoxyribonucleic&nbsp;acid&nbsp;(DNA). The&nbsp;incorporation&nbsp;of&nbsp;5-FU&nbsp;also leads&nbsp;to&nbsp;inhibition&nbsp;of&nbsp;RNA&nbsp;and protein&nbsp;synthesis.&nbsp;Since&nbsp;DNA&nbsp;and&nbsp;RNA&nbsp;areessential&nbsp;for&nbsp;cell&nbsp;division&nbsp;and&nbsp;growth,&nbsp;the&nbsp;effect&nbsp;of 5-FU may be to create a thymidine deficiency that provokes unbalanced growth and death of a cell. The effects of DNA and RNA deprivation are most marked on those cells which proliferate more rapidly and which metabolise 5-FU at a more rapid rate.</p><p><u>Colon&nbsp;and&nbsp;colorectal&nbsp;cancer:</u></p><p><em><u>Monotherapy&nbsp;with&nbsp;capecitabine&nbsp;in&nbsp;adjuvant&nbsp;colon&nbsp;cancer</u></em></p><p>Data&nbsp;from&nbsp;one&nbsp;multicentre,&nbsp;randomised,&nbsp;controlled&nbsp;phase&nbsp;III&nbsp;clinical&nbsp;trial&nbsp;in&nbsp;patients&nbsp;with&nbsp;stage III (Dukes&#39; C) colon cancer supports the use of capecitabine for the adjuvant treatment of patients with colon cancer. In this trial, 1987 patients were randomised to treatment with capecitabine&nbsp;(1250&nbsp;mg/m2&nbsp;twice&nbsp;daily&nbsp;for&nbsp;2&nbsp;weeks&nbsp;followed&nbsp;by&nbsp;a&nbsp;1-&nbsp;week&nbsp;rest&nbsp;period&nbsp;and&nbsp;given&nbsp;as 3-week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m<sup>2</sup>&nbsp;leucovorin&nbsp;IV followed by&nbsp;425 mg/m<sup>2</sup>&nbsp;intravenous bolus 5-FU, on&nbsp;days 1 to 5, every&nbsp;28 days for 24&nbsp;weeks).&nbsp;Capecitabine wasat least equivalent&nbsp;to&nbsp;IV 5-FU/LV in&nbsp;disease-free survival&nbsp;in per protocol population (hazard ratio 0.92; 95% CI 0.80- 1.06). In the all-randomised population,&nbsp;tests&nbsp;for&nbsp;difference&nbsp;of&nbsp;capecitabine&nbsp;vs&nbsp;5-FU/LV&nbsp;in&nbsp;disease-free&nbsp;andoverall&nbsp;survival showed&nbsp;hazard&nbsp;ratios&nbsp;of&nbsp;0.88&nbsp;(95%&nbsp;CI&nbsp;0.77&nbsp;&ndash;&nbsp;1.01;&nbsp;p&nbsp;=&nbsp;0.068)&nbsp;and&nbsp;0.86&nbsp;(95%&nbsp;CI&nbsp;0.74&nbsp;&ndash;&nbsp;1.01;&nbsp;p</p><p>= 0.060), respectively. The median follow up at the time of the analysis was 6.9 years. In a preplanned multivariate Cox analysis, superiority of capecitabine compared with bolus 5- FU/LV was demonstrated. The following factors&nbsp;were pre-specified in the statistical&nbsp;analysis plan for inclusion in&nbsp;the model: age,&nbsp;time fromsurgery&nbsp;to randomization, gender, CEA&nbsp;levels at baseline, lymph nodes at baseline, and country. In the all-randomised population, capecitabine&nbsp;was&nbsp;shown&nbsp;to&nbsp;be&nbsp;superior&nbsp;to&nbsp;5FU/LV&nbsp;for&nbsp;disease-free&nbsp;survival&nbsp;(hazard&nbsp;ratio0.849; 95%&nbsp;CI&nbsp;0.739&nbsp;-&nbsp;0.976;&nbsp;p&nbsp;=&nbsp;0.0212),&nbsp;as&nbsp;well&nbsp;as&nbsp;for&nbsp;overall&nbsp;survival&nbsp;(hazard&nbsp;ratio&nbsp;0.828;&nbsp;95%&nbsp;CI</p><p>0.705&nbsp;- 0.971;&nbsp;p&nbsp;=&nbsp;0.0203).</p><p><em><u>Combination&nbsp;therapy in&nbsp;adjuvant&nbsp;colon&nbsp;cancer</u></em></p><p>Data&nbsp;from&nbsp;one multicentre, randomised, controlled phase 3 clinical&nbsp;trial&nbsp;in&nbsp;patients with&nbsp;stage III (Dukes&#39; C) colon cancer supports the use of capecitabine in combination with oxaliplatin (XELOX) for the adjuvant treatment of patients with colon cancer (NO16968 study). In this trial, 944 patients were randomised to 3-week cycles for 24 weeks with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 1-week rest period) in combination with oxaliplatin (130 mg/m<sup>2</sup>&nbsp;intravenous infusion over 2-hours on day 1 every 3 weeks); 942 patients&nbsp;were&nbsp;randomised&nbsp;to&nbsp;bolus&nbsp;5-FU&nbsp;and&nbsp;leucovorin.&nbsp;In&nbsp;the&nbsp;primary&nbsp;analysis&nbsp;for&nbsp;DFS&nbsp;in&nbsp;the ITT population, XELOX was shown&nbsp;to be significantly&nbsp;superior to 5-FU/LV (HR=0.80, 95% CI= [0.69; 0.93]; p=0.0045). The 3 year DFS rate was 71% for XELOX versus 67% for 5-&nbsp;FU/LV.</p><p>The&nbsp;analysis&nbsp;for&nbsp;the&nbsp;secondary&nbsp;endpoint&nbsp;of&nbsp;RFS&nbsp;supports&nbsp;these&nbsp;results&nbsp;with&nbsp;a&nbsp;HR&nbsp;of&nbsp;0.78&nbsp;(95% CI=[0.67; 0.92]; p=0.0024) for XELOX vs. 5-FU/LV. XELOX showed a trend towards superior OS with a HR of&nbsp;0.87 (95% CI=[0.72; 1.05];&nbsp;p=0.1486) which translates into a 13% reduction&nbsp;in&nbsp;risk&nbsp;of&nbsp;death.&nbsp;The&nbsp;5&nbsp;year&nbsp;OS&nbsp;rate&nbsp;was&nbsp;78%&nbsp;forXELOX&nbsp;versus&nbsp;74% for&nbsp;5-FU/LV. The efficacy data is based on a median observation time of&nbsp;59 months for OS and 57 months for&nbsp;DFS.&nbsp;The&nbsp;rate&nbsp;of&nbsp;withdrawal&nbsp;due&nbsp;to&nbsp;adverse&nbsp;events&nbsp;was higher in&nbsp;the&nbsp;XELOX&nbsp;combination&nbsp;therapy arm (21%) as compared with that of the 5-FU/LV monotherapy arm (9%) in the ITT&nbsp;population.</p><p><u>Monotherapy&nbsp;with&nbsp;capecitabine&nbsp;in&nbsp;metastatic&nbsp;colorectal&nbsp;cancer</u></p><p>Data from two identically-designed, multicentre, randomised, controlled phase III clinical trials&nbsp;(SO14695;SO14796)&nbsp;support&nbsp;the&nbsp;use&nbsp;of&nbsp;capecitabine&nbsp;for&nbsp;first&nbsp;line&nbsp;treatment&nbsp;of&nbsp;metastatic colorectal&nbsp;cancer.&nbsp;In&nbsp;these&nbsp;trials,603&nbsp;patients&nbsp;were randomised&nbsp;to&nbsp;treatment with&nbsp;capecitabine (1250 mg/m<sup>2</sup>&nbsp;twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles).&nbsp;604&nbsp;patients&nbsp;were&nbsp;randomised&nbsp;to&nbsp;treatment&nbsp;with&nbsp;5-FU&nbsp;andleucovorin&nbsp;(Mayo&nbsp;regimen: 20 mg/m<sup>2</sup>&nbsp;leucovorin intravenous followed by&nbsp;425 mg/m<sup>2</sup>&nbsp;intravenous bolus 5-FU, on days 1 to 5, every 28 days). The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs. 16.7% (Mayo regimen); p &lt;0.0002. The median time to progression was 140 days (capecitabine) vs. 144 days (Mayo regimen). Median survival was 392 days (capecitabine) vs. 391 days (Mayo regimen). Currently, no comparative data are available on capecitabine monotherapy in colorectal cancer in comparison with first line combination regimens.</p><p><u>Combination&nbsp;therapy&nbsp;in&nbsp;first-line&nbsp;treatment&nbsp;of&nbsp;metastatic&nbsp;colorectal&nbsp;cancer</u></p><p>Data from a multicentre, randomised, controlled phase III clinical study (NO16966) support the&nbsp;use&nbsp;ofcapecitabine in&nbsp;combination&nbsp;with&nbsp;oxaliplatin&nbsp;or&nbsp;in&nbsp;combination&nbsp;with&nbsp;oxaliplatin&nbsp;and bevacizumab for the first-line treatment of metastatic colorectal cancer. The study contained two parts: an initial 2-arm part in which 634 patients were randomised to two different treatment groups, including XELOX or FOLFOX-4, and a subsequent 2x2 factorial part in which 1401 patients were randomised to four different treatment groups, including XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus bevacizumab, and FOLFOX-4 plus bevacizumab. See table 6 for treatment regimens.</p><p><strong>Table&nbsp;6&nbsp;Treatment regimens&nbsp;in&nbsp;study&nbsp;NO16966&nbsp;(mCRC)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Treatment</strong></p></td><td style="vertical-align:top"><p><strong>Starting&nbsp;Dose</strong></p></td><td style="vertical-align:top"><p><strong>Schedule</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>FOLFOX-4</p><p>or</p><p>FOLFOX-4&nbsp;+</p><p>Bevacizumab</p></td><td style="vertical-align:top"><p>Oxaliplatin</p></td><td style="vertical-align:top"><p>85&nbsp;mg/m<sup>2</sup>&nbsp;intravenous&nbsp;2&nbsp;hr</p></td><td rowspan="3" style="vertical-align:top"><p>Oxaliplatin on Day 1, every 2 weeks Leucovorin on Days 1 and 2, every 2 weeks 5-fluorouracil intravenous bolus/infusion, each on Days 1 and 2, every 2 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Leucovorin</p></td><td style="vertical-align:top"><p>200&nbsp;mg/m<sup>2</sup>&nbsp;intravenous&nbsp;2&nbsp;hr</p></td></tr><tr><td style="vertical-align:top"><p>5-Fluorouracil</p></td><td style="vertical-align:top"><p>400 mg/m<sup>2</sup>&nbsp;intravenous bolus,&nbsp;followed&nbsp;by&nbsp;600&nbsp;mg/</p><p>m<sup>2</sup>&nbsp;intravenous&nbsp;22&nbsp;hr</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:1375px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:99px"><p>Placebo or&nbsp;Bevacizumab</p></td><td style="vertical-align:top; width:305px"><p>5&nbsp;mg/kg&nbsp;intravenous&nbsp;30-90&nbsp;mins</p></td><td style="vertical-align:top; width:875px"><p>Day&nbsp;1,&nbsp;prior&nbsp;to&nbsp;FOLFOX-4,&nbsp;every&nbsp;2&nbsp;weeks</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>XELOX</p><p>or&nbsp;XELOX</p><p>+</p><p>Bevacizumab</p></td><td style="vertical-align:top; width:99px"><p>Oxaliplatin</p></td><td style="vertical-align:top; width:305px"><p>130&nbsp;mg/m2&nbsp;intravenous&nbsp;2&nbsp;hr</p></td><td rowspan="2" style="vertical-align:top; width:875px"><p>Oxaliplatin on Day 1, every 3 weeks Capecitabine&nbsp;oral&nbsp;twice&nbsp;daily&nbsp;for&nbsp;2&nbsp;weeks (followed by 1 week off-treatment)</p></td></tr><tr><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong></p><p>Capecitabine</p></td><td style="vertical-align:top; width:305px"><p>1000&nbsp;mg/m<sup>2</sup>&nbsp;oral&nbsp;twice&nbsp;daily</p></td></tr><tr><td style="vertical-align:top; width:99px"><p>Placebo or&nbsp;Bevacizumab</p></td><td style="vertical-align:top; width:305px"><p>7.5&nbsp;mg/kg&nbsp;intravenous&nbsp;30-90&nbsp;mins</p></td><td style="vertical-align:top; width:875px"><p>Day&nbsp;1,&nbsp;prior&nbsp;to&nbsp;XELOX,&nbsp;every&nbsp;3&nbsp;weeks</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:1372px"><p>5-Fluorouracil:&nbsp;intravenous&nbsp;bolus&nbsp;injection&nbsp;immediately&nbsp;after&nbsp;leucovorin</p></td></tr></tbody></table><p>&nbsp;</p><p>Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival in the eligible&nbsp;patient population&nbsp;and&nbsp;the intent-to-treat population&nbsp;(see&nbsp;table&nbsp;7). The&nbsp;results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see table 7). A comparison of XELOX plus bevacizumab versus FOLFOX-4 plus bevacizumab was a pre- specified exploratory analysis. In this treatment subgroup comparison, XELOX plus bevacizumabwas&nbsp;similar&nbsp;compared&nbsp;to&nbsp;FOLFOX-4&nbsp;plus&nbsp;bevacizumab&nbsp;in&nbsp;terms&nbsp;of&nbsp;progression- free survival (hazard ratio 1.01; 97.5% CI 0.84 - 1.22). The median follow up at the time of the primary analyses in the intent-to-treat population was 1.5 years; data from analyses following an additional 1 year of follow up are also included in table 7. However, the on- treatment PFS analysis did not confirm the results of the general PFS and OS analysis: the hazard ratio of XELOX versus FOLFOX-4 was 1.24 with 97.5% CI 1.07 - 1.44. Although sensitivity analyses show that differences in regimen schedules and timing of tumor assessments impact the on treatment PFS analysis, a full explanation for this result has not been found.</p><p>Table&nbsp;7&nbsp;Key&nbsp;efficacy&nbsp;results&nbsp;for&nbsp;the non-inferiority&nbsp;analysis&nbsp;of&nbsp;Study&nbsp;NO16966</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>PRIMARY&nbsp;ANALYSIS</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:124px"><p>&nbsp;</p></td><td style="vertical-align:top; width:1px"><p>XELOX/XELOX+</p></td><td style="vertical-align:top; width:478.96875px"><p>FOLFOX-4/FOLFOX-</p></td><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:1px"><p>P/&nbsp;XELOX+BV</p></td><td style="vertical-align:top; width:478.96875px"><p>4+P/&nbsp;FOLFOX-4+BV</p></td></tr><tr><td style="vertical-align:top; width:1px"><p>(EPP*:&nbsp;N=967;</p></td><td style="vertical-align:top; width:478.96875px"><p>(EPP*:&nbsp;N&nbsp;=&nbsp;937;&nbsp;ITT**:</p></td></tr><tr><td style="vertical-align:top; width:1px"><p>ITT**:&nbsp;N=1017)</p></td><td style="vertical-align:top; width:478.96875px"><p>N=&nbsp;1017)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:609px"><tbody><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top; width:256px"><p><strong>Median&nbsp;Time&nbsp;to&nbsp;Event&nbsp;(Days)</strong></p></td><td style="vertical-align:top; width:258px"><p><strong>HR&nbsp;(97.5%&nbsp;CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top; width:606px"><p><strong>Parameter:&nbsp;Progression-free&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p></td><td style="vertical-align:top"><p>241</p></td><td style="vertical-align:top; width:150px"><p>259</p></td><td style="vertical-align:top; width:258px"><p>1.05&nbsp;(0.94;&nbsp;1.18)</p></td></tr><tr><td style="vertical-align:top"><p>ITT</p></td><td style="vertical-align:top"><p>244</p></td><td style="vertical-align:top; width:150px"><p>259</p></td><td style="vertical-align:top; width:258px"><p>1.04&nbsp;(0.93;&nbsp;1.16)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:606px"><p><strong>Parameter:&nbsp;Overall&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p></td><td style="vertical-align:top"><p>577</p></td><td style="vertical-align:top; width:150px"><p>549</p></td><td style="vertical-align:top; width:258px"><p>0.97&nbsp;(0.84;&nbsp;1.14)</p></td></tr><tr><td style="vertical-align:top"><p>ITT</p></td><td style="vertical-align:top"><p>581</p></td><td style="vertical-align:top; width:150px"><p>553</p></td><td style="vertical-align:top; width:258px"><p>0.96&nbsp;(0.83;&nbsp;1.12)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:606px"><p><strong>ADDITIONAL&nbsp;1&nbsp;YEAR&nbsp;OF&nbsp;FOLLOW&nbsp;UP</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top; width:256px"><p><strong>Median&nbsp;Time&nbsp;to&nbsp;Event&nbsp;(Days)</strong></p></td><td style="vertical-align:top; width:258px"><p><strong>HR&nbsp;(97.5%&nbsp;CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top; width:606px"><p><strong>Parameter:&nbsp;Progression-free&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p></td><td style="vertical-align:top"><p>242</p></td><td style="vertical-align:top; width:150px"><p>259</p></td><td style="vertical-align:top; width:258px"><p>1.02&nbsp;(0.92;&nbsp;1.14)</p></td></tr><tr><td style="vertical-align:top"><p>ITT</p></td><td style="vertical-align:top"><p>244</p></td><td style="vertical-align:top; width:150px"><p>259</p></td><td style="vertical-align:top; width:258px"><p>1.01&nbsp;(0.91;&nbsp;1.12)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:606px"><p><strong>Parameter:&nbsp;Overall&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top; width:150px"><p>594</p></td><td style="vertical-align:top; width:258px"><p>1.00&nbsp;(0.88;&nbsp;1.13)</p></td></tr><tr><td style="vertical-align:top"><p>ITT</p></td><td style="vertical-align:top"><p>602</p></td><td style="vertical-align:top; width:150px"><p>596</p></td><td style="vertical-align:top; width:258px"><p>0.99&nbsp;(0.88;&nbsp;1.12)</p></td></tr></tbody></table><p>*EPP=eligible&nbsp;patient&nbsp;population;&nbsp;**ITT=intent-to-treat&nbsp;population</p><p>In a randomised, controlled phase III study (CAIRO), the effect of using capecitabine at a starting&nbsp;dose&nbsp;of&nbsp;1000mg/m<sup>2</sup>&nbsp;for&nbsp;2&nbsp;weeks&nbsp;every&nbsp;3 weeks in&nbsp;combination&nbsp;with&nbsp;irinotecan&nbsp;for&nbsp;the first-line&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;withmetastatic&nbsp;colorectal&nbsp;cancer&nbsp;was&nbsp;studied.&nbsp;820&nbsp;Patients&nbsp;were randomised to receive either sequential&nbsp;treatment (n=410) or combination&nbsp;treatment (n=410). Sequential&nbsp;treatment consisted&nbsp;of&nbsp;first line&nbsp;capecitabine&nbsp;(1250&nbsp;mg/m<sup>2</sup>twice&nbsp;daily&nbsp;for&nbsp;14&nbsp;days), second-line&nbsp;irinotecan&nbsp;(350&nbsp;mg/m2&nbsp;on&nbsp;day&nbsp;1),&nbsp;and&nbsp;third-line&nbsp;combination&nbsp;of&nbsp;capecitabine(1000 mg/m<sup>2</sup>&nbsp;twice&nbsp;daily&nbsp;for&nbsp;14&nbsp;days)&nbsp;with&nbsp;oxaliplatin&nbsp;(130 mg/m<sup>2</sup>&nbsp;on&nbsp;day&nbsp;1).&nbsp;Combination&nbsp;treatment consisted of first-line capecitabine (1000 mg/m<sup>2</sup>&nbsp;twice daily for 14 days) combined with irinotecan&nbsp;(250 mg /m<sup>2</sup>&nbsp;on day&nbsp;1) (XELIRI) and second-line capecitabine (1000 mg/m<sup>2</sup>&nbsp;twice daily for 14 days) plus oxaliplatin (130 mg/m<sup>2</sup>&nbsp;on day 1). All treatment cycles were administered at intervals of 3 weeks. In first-line treatment the median progression-free survival in the intent-to-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for capecitabine monotherapy&nbsp;and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI. However this was associated with an increased incidence of gastrointestinal toxicity and neutropenia during first line treatment with&nbsp;XELIRI (26%&nbsp;and 11% for XELIRI&nbsp;and first line&nbsp;capecitabine&nbsp;respectively).</p><p>The XELIRI has been compared with 5-FU + irinotecan (FOLFIRI) in three randomised studies in patients with metastatic colorectal cancer. The XELIRI regimens included capecitabine 1000 mg/m<sup>2</sup>&nbsp;twice daily on days 1 to 14 of a three-week cycle combined with irinotecan 250 mg/m<sup>2</sup>&nbsp;on day1. In the largest study (BICC-C), patients were randomised to receive either open label FOLFIRI (n=144), bolus 5-FU (mIFL) (n=145) or XELIRI (n=141) and were additionally randomised to receive either double-blind treatment with celecoxib or placebo. Median PFS was 7.6 months for FOLFIRI, 5.9 months for mIFL (p=0.004) for the comparison with FOLFIRI), and 5.8 months for XELIRI (p=0.015). Median OS was 23.1 months&nbsp;for&nbsp;FOLFIRI,&nbsp;17.6&nbsp;months&nbsp;for&nbsp;mIFL(p=0.09),&nbsp;and&nbsp;18.9&nbsp;months&nbsp;for&nbsp;XELIRI (p=0.27). Patients treated with XELIRI experienced excessive gastrointestinal toxicity compared with FOLFIRI (diarrhoea 48% and 14% for XELIRI and FOLFIRI respectively).</p><p>In the EORTC study patients were randomised to receive either open label FOLFIRI (n=41) or XELIRI (n=44) with additional randomisation to either double-blind treatment with celecoxib or placebo. Median PFS and overall survival (OS) times were shorter for XELIRI versus FOLFIRI (PFS 5.9 versus 9.6 months and OS 14.8versus 19.9 months), in&nbsp;addition&nbsp;to which excessive rates of diarrhoea were reported in patients receiving the XELIRI regimen (41% XELIRI, 5.1% FOLFIRI).</p><p>In the study published by Skof et al, patients were randomised to receive either FOLFIRI or XELIRI . Overall response rate was 49% in the XELIRI and 48% in the FOLFIRI arm (p=0.76). At the end of treatment, 37% of patients in the XELIRI and 26% of patients in the FOLFIRI arm were without evidence of the disease (p=0.56). Toxcity was similar between treatments&nbsp;with&nbsp;the&nbsp;exception&nbsp;of&nbsp;neutropenia&nbsp;reported&nbsp;more&nbsp;commonly&nbsp;in&nbsp;patientstreated&nbsp;with&nbsp;FOLFIRI.</p><p>Montagnani et al used the results from the above three studies to provide an overall analysis of&nbsp;randomized studies comparing FOLFIRI and XELIRI treatment regimens in the treatment of&nbsp;mCRC.&nbsp;A&nbsp;significant&nbsp;reductionin&nbsp;the&nbsp;risk&nbsp;of&nbsp;progression&nbsp;was&nbsp;associated&nbsp;with&nbsp;FOLFIRI&nbsp;(HR, 0.76;&nbsp;95%CI,&nbsp;0.62-0.95;&nbsp;P&nbsp;&lt;0.01),&nbsp;a&nbsp;result&nbsp;partly&nbsp;dueto&nbsp;poor&nbsp;tolerance&nbsp;to&nbsp;the&nbsp;XELIRI&nbsp;regimens&nbsp;used.</p><p>Data from a randomised clinical study (Souglakos et al, 2012) comparing FOLFIRI + bevacizumab with XELIRI&nbsp;+&nbsp;bevacizumab showed&nbsp;no&nbsp;significant&nbsp;differences&nbsp;in PFS&nbsp;or&nbsp;OS&nbsp;between treatments.</p><p>Patients were randomised to receive either FOLFIRI plus bevacizumab (Arm-A, n=167) or XELIRI plus bevacizumab (Arm-B, n-166). For Arm B, the XELIRI regimen used capecitabine 1000 mg/m2 twice daily for 14 days + irinotecan 250 mg/m2 on day 1. Median progressionfree survival (PFS) was 10.0 and 8.9 months; p=0.64, overall survival 25.7 and 27.5 months; p=0.55 and response rates 45.5 and 39.8%; p=0.32 for FOLFIRI-Bev and XELIRI-Bev, respectively. Patients treated with XELIRI + bevacizumab reported a significantly higher incidence of&nbsp;diarrhoea, febrile neutropenia and hand-foot skin reactions than patients treated with FOLFIRI + bevacizumab with significantly increased treatment delays, dose reductions and treatment discontinuations.</p><p>Data&nbsp;from&nbsp;a&nbsp;multicentre,&nbsp;randomised, controlled phase&nbsp;II study&nbsp;(AIO&nbsp;KRK&nbsp;0604) supports&nbsp;the use&nbsp;ofcapecitabine&nbsp;at&nbsp;a&nbsp;starting&nbsp;dose&nbsp;of&nbsp;800&nbsp;mg/m<sup>2</sup>&nbsp;for 2&nbsp;weeks&nbsp;every&nbsp;3&nbsp;weeks in&nbsp;combination with&nbsp;irinotecan&nbsp;andbevacizumab&nbsp;for&nbsp;the&nbsp;first-line&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;metastatic colorectal&nbsp;cancer.&nbsp;120&nbsp;Patients&nbsp;wererandomised&nbsp;to&nbsp;a&nbsp;modified&nbsp;XELIRI&nbsp;regimen&nbsp;with capecitabine&nbsp;800&nbsp;mg/m<sup>2</sup>&nbsp;twice&nbsp;daily&nbsp;for&nbsp;two&nbsp;weeksfollowed&nbsp;by&nbsp;a&nbsp;7-day&nbsp;rest&nbsp;period),&nbsp;irinotecan (200&nbsp;mg/m<sup>2</sup>&nbsp;as&nbsp;a&nbsp;30 minute&nbsp;infusion&nbsp;on&nbsp;day&nbsp;1&nbsp;every&nbsp;3 weeks), andbevacizumab&nbsp;(7.5&nbsp;mg/kg&nbsp;as a&nbsp;30&nbsp;to&nbsp;90&nbsp;minute&nbsp;infusion&nbsp;on&nbsp;day&nbsp;1&nbsp;every&nbsp;3&nbsp;weeks&nbsp;;&nbsp;127&nbsp;patients&nbsp;were&nbsp;randomised&nbsp;totreatment with capecitabine (1000 mg/m<sup>2</sup>&nbsp;twice daily for two weeks followed by a 7-day rest period),oxaliplatin (130 mg/m<sup>2</sup>&nbsp;as a 2 hour infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks). Following a mean duration of follow-up&nbsp;for&nbsp;the&nbsp;study&nbsp;population&nbsp;of26.2&nbsp;months, treatment responses&nbsp;were&nbsp;as&nbsp;shown&nbsp;below:</p><p><strong>Table 8 Key efficacy results for AIO KRK study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>XELOX&nbsp;+&nbsp;bevacizumab</em></strong></p><p>&nbsp;</p><p><strong><em>(ITT:&nbsp;N=127)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Modified&nbsp;XELIRI+bevacizumab&nbsp;(ITT: N= 120)</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Hazard&nbsp;ratio 95% CI</em></strong></p><p><strong><em>P&nbsp;value</em></strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Progression-free&nbsp;Survival&nbsp;after&nbsp;6&nbsp;months</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><em>ITT&nbsp;95%&nbsp;CI</em></p></td><td style="vertical-align:top"><p><em>76%</em></p><p><em>69&nbsp;-&nbsp;84%</em></p></td><td style="vertical-align:top"><p><em>84%</em></p><p><em>77&nbsp;-&nbsp;90%</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><em>-</em></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Median&nbsp;progression&nbsp;free&nbsp;survival</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><em>ITT&nbsp;95%&nbsp;CI</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><em>10.4&nbsp;months 9.0 - 12.0</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><em>12.1&nbsp;months 10.8&nbsp;-&nbsp;13.2</em></p></td><td style="vertical-align:top"><p><em>0.93</em></p><p><em>0.82&nbsp;-&nbsp;1.07</em></p><p><em>P=0.30</em></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Median&nbsp;overall&nbsp;survival</em></strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><em>ITT&nbsp;95%&nbsp;CI</em></p></td><td style="vertical-align:top; width:159px"><p>&nbsp;</p><p><em>24.4&nbsp;months&nbsp;19.3-30.7</em></p></td><td style="vertical-align:top; width:300px"><p>&nbsp;</p><p><em>25.5&nbsp;months&nbsp;21.0-31.0</em></p></td><td style="vertical-align:top; width:151px"><p><em>0.90</em></p><p><em>0.67&nbsp;-&nbsp;1.19</em></p><p><em>P=0.45</em></p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Combination&nbsp;therapy&nbsp;in&nbsp;second-line&nbsp;treatment&nbsp;of&nbsp;metastatic&nbsp;colorectal&nbsp;cancer</u></em></p><p>Data from a multicentre, randomised, controlled phase III clinical study (NO16967) support the use of capecitabine in combination with oxaliplatin for the second-line treatment of metastastic colorectal cancer. In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first line therapy&nbsp;were randomised to treatment with XELOX or FOLFOX-4. For the&nbsp;dosing&nbsp;schedule&nbsp;of&nbsp;XELOX&nbsp;and&nbsp;FOLFOX-4&nbsp;(without&nbsp;addition&nbsp;of&nbsp;placebo&nbsp;orbevacizumab), refer to table 6. XELOX was demonstrated to be non-inferior to FOLFOX-4 in terms of progression-free survival in the per-protocol population and intent-to-treat population (see table 9). The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival&nbsp;(see table 9). The median follow up at the&nbsp;time of&nbsp;the primary&nbsp;analyses in&nbsp;the intent- to-treat population was 2.1 years; data from analyses following an additional 6 months of follow up are also included in table 9.</p><p><strong>Table&nbsp;9&nbsp;Key&nbsp;efficacy&nbsp;results&nbsp;for&nbsp;the non-inferiority&nbsp;analysis&nbsp;of&nbsp;Study&nbsp;NO16967</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>PRIMARY&nbsp;ANALYSIS</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>XELOX</p><p>(PPP*:&nbsp;N=251;&nbsp;ITT**:&nbsp;N=313)</p></td><td style="vertical-align:top"><p>FOLFOX-4&nbsp;(PPP*:&nbsp;N&nbsp;=</p><p>252;&nbsp;ITT**:&nbsp;N=&nbsp;314)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Median&nbsp;Time&nbsp;to&nbsp;Event&nbsp;(Days)</strong></p></td><td style="vertical-align:top"><p><strong>HR&nbsp;(95%&nbsp;CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter:&nbsp;Progression-free&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>PPP</p></td><td style="vertical-align:top"><p>154</p></td><td style="vertical-align:top"><p>168</p></td><td style="vertical-align:top"><p>1.03&nbsp;(0.87;&nbsp;1.24)</p></td></tr><tr><td style="vertical-align:top"><p>ITT</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>146</p></td><td style="vertical-align:top"><p>0.97&nbsp;(0.83;&nbsp;1.14)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter:&nbsp;Overall&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top"><p>PPP</p></td><td style="vertical-align:top"><p>388</p></td><td style="vertical-align:top"><p>401</p></td><td style="vertical-align:top"><p>1.07&nbsp;(0.88;&nbsp;1.31)</p></td></tr><tr><td style="vertical-align:top"><p>ITT</p></td><td style="vertical-align:top"><p>363</p></td><td style="vertical-align:top"><p>382</p></td><td style="vertical-align:top"><p>1.03&nbsp;(0.87;&nbsp;1.23)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ADDITIONAL&nbsp;6&nbsp;MONTHS&nbsp;OF&nbsp;FOLLOWUP</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Population</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Median&nbsp;Time&nbsp;to&nbsp;Event&nbsp;(Days)</strong></p></td><td style="vertical-align:top"><p><strong>HR(95%&nbsp;CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter:&nbsp;Progression-free&nbsp;Survival</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:497px"><tbody><tr><td style="vertical-align:top; width:89px"><p>PPP</p></td><td style="vertical-align:top; width:168px"><p>154</p></td><td style="vertical-align:top; width:131px"><p>166</p></td><td style="vertical-align:top; width:108px"><p>1.04&nbsp;(0.87;&nbsp;1.24)</p></td></tr><tr><td style="vertical-align:top; width:89px"><p>ITT</p></td><td style="vertical-align:top; width:168px"><p>143</p></td><td style="vertical-align:top; width:131px"><p>146</p></td><td style="vertical-align:top; width:108px"><p>0.97&nbsp;(0.83;&nbsp;1.14)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:494px"><p><strong>Parameter:&nbsp;Overall&nbsp;Survival</strong></p></td></tr><tr><td style="vertical-align:top; width:89px"><p>PPP</p></td><td style="vertical-align:top; width:168px"><p>393</p></td><td style="vertical-align:top; width:131px"><p>402</p></td><td style="vertical-align:top; width:108px"><p>1.05&nbsp;(0.88;&nbsp;1.27)</p></td></tr><tr><td style="vertical-align:top; width:89px"><p>ITT</p></td><td style="vertical-align:top; width:168px"><p>363</p></td><td style="vertical-align:top; width:131px"><p>382</p></td><td style="vertical-align:top; width:108px"><p>1.02&nbsp;(0.86;&nbsp;1.21)</p></td></tr></tbody></table><p>*PPP=per-protocol&nbsp;population;&nbsp;**ITT=intent-to-treat&nbsp;population</p><p>&nbsp;</p><p><u>Advanced&nbsp;gastric&nbsp;cancer:</u></p><p>Data&nbsp;from&nbsp;a&nbsp;multicentre,&nbsp;randomised,&nbsp;controlled&nbsp;phase&nbsp;III&nbsp;clinical&nbsp;trial&nbsp;in&nbsp;patients&nbsp;with advanced&nbsp;gastriccancer&nbsp;supports&nbsp;the&nbsp;use&nbsp;of&nbsp;capecitabine&nbsp;for&nbsp;the&nbsp;first-line&nbsp;treatment&nbsp;of&nbsp;advanced gastric&nbsp;cancer&nbsp;(ML17032).&nbsp;In&nbsp;thistrial,&nbsp;160&nbsp;patients&nbsp;were&nbsp;randomised&nbsp;to&nbsp;treatment&nbsp;with capecitabine&nbsp;(1000&nbsp;mg/m<sup>2</sup>&nbsp;twice&nbsp;daily&nbsp;for&nbsp;2&nbsp;weeksfollowed&nbsp;by&nbsp;a&nbsp;7-day&nbsp;rest&nbsp;period)&nbsp;and cisplatin&nbsp;(80&nbsp;mg/m<sup>2</sup>&nbsp;as&nbsp;a&nbsp;2-hour&nbsp;infusion&nbsp;every&nbsp;3&nbsp;weeks).&nbsp;A&nbsp;total&nbsp;of156&nbsp;patients&nbsp;were randomised to treatment with 5-FU (800 mg/m<sup>2</sup>&nbsp;per day, continuous infusion on days 1 to 5 every&nbsp;3&nbsp;weeks)&nbsp;and&nbsp;cisplatin&nbsp;(80&nbsp;mg/m2&nbsp;as&nbsp;a&nbsp;2-hour&nbsp;infusion&nbsp;on&nbsp;day&nbsp;1,&nbsp;every&nbsp;3&nbsp;weeks). Capecitabine&nbsp;incombination&nbsp;with&nbsp;cisplatin&nbsp;was&nbsp;non-inferior&nbsp;to&nbsp;5-FU&nbsp;in&nbsp;combination&nbsp;with cisplatin in terms of progression-free survival in the per protocol analysis (hazard ratio 0.81; 95% CI 0.63 - 1.04). The median progression-free survival was 5.6 months (capecitabine +&nbsp;cisplatin)&nbsp;versus&nbsp;5.0&nbsp;months&nbsp;(5-FU&nbsp;+&nbsp;cisplatin).&nbsp;The&nbsp;hazard&nbsp;ratiofor&nbsp;duration&nbsp;of&nbsp;survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio&nbsp;0.85; 95% CI 0.64 - 1.13). The median duration of survival was 10.5 months (capecitabine + cisplatin) versus 9.3 months (5-FU + cisplatin).</p><p>Data from a randomised multicentre, phase III study comparing capecitabine to 5-FU and oxaliplatin&nbsp;to&nbsp;cisplatinin&nbsp;patients&nbsp;with&nbsp;advanced&nbsp;gastric&nbsp;cancer&nbsp;supports&nbsp;the&nbsp;use&nbsp;of&nbsp;capecitabine for the first-line treatment of advanced gastric cancer (REAL-2). In this trial, 1002 patients were randomised in a 2x2 factorial design to one of the following 4 arms:</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->ECF: epirubicin (50 mg/ m<sup>2</sup>&nbsp;as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m<sup>2</sup>&nbsp;as a two&nbsp;hour&nbsp;infusionon&nbsp;day&nbsp;1&nbsp;every&nbsp;3&nbsp;weeks)&nbsp;and&nbsp;5-FU&nbsp;(200&nbsp;mg/m<sup>2</sup>&nbsp;daily&nbsp;given&nbsp;by&nbsp;continuous infusion via a central line).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->ECX: epirubicin (50 mg/m<sup>2</sup>&nbsp;as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m<sup>2</sup>&nbsp;as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m2 twice daily&nbsp;continuously).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->EOF: epirubicin (50 mg/m<sup>2</sup>&nbsp;as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m<sup>2</sup>&nbsp;given as a 2 hour infusion on day&nbsp;1 every&nbsp;three weeks), and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->EOX: epirubicin (50 mg/m<sup>2</sup>&nbsp;as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m<sup>2</sup>&nbsp;given&nbsp;as&nbsp;a&nbsp;2 hourinfusion&nbsp;on&nbsp;day&nbsp;1&nbsp;every&nbsp;three&nbsp;weeks),&nbsp;and&nbsp;capecitabine&nbsp;(625&nbsp;mg/m2&nbsp;twice daily continuously).</p><p>The primary efficacy analyses in the per protocol population demonstrated non-inferiority in overall survival for capecitabine- vs 5-FU-based regimens (hazard ratio 0.86; 95% CI 0.8 - 0.99) and for oxaliplatin- vs cisplatin-based regimens (hazard ratio 0.92; 95% CI 0.80 - 1.1). The median&nbsp;overall&nbsp;survival&nbsp;was&nbsp;10.9&nbsp;months incapecitabine-based&nbsp;regimens&nbsp;and&nbsp;9.6 months in 5-FU based regimens. The median overall survival was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin-based regimens.</p><p>Capecitabine&nbsp;has&nbsp;also&nbsp;been&nbsp;used&nbsp;in&nbsp;combination&nbsp;with&nbsp;oxaliplatin&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;advanced gastric cancer. Studies with capecitabine monotherapy indicate that capecitabine has activity in advanced gastric cancer.</p><p><u>Colon,&nbsp;colorectal&nbsp;and&nbsp;advanced&nbsp;gastric&nbsp;cancer:&nbsp;meta-analysis</u></p><p>A meta-analysis of six clinical trials (studies SO14695, SO14796, M66001, NO16966, NO16967, M17032) supports capecitabine replacing 5-FU in mono- and combination treatment in gastrointestinal cancer. The pooled analysis includes 3097 patients treated with capecitabine-containing regimens and 3074 patients treated with 5-FU-containing regimens. Median overall survival time was 703 days (95% CI: 671; 745) in patients treated with capecitabine-containing&nbsp;regimens&nbsp;and&nbsp;683&nbsp;days&nbsp;(95%&nbsp;CI:&nbsp;646; 715)&nbsp;in&nbsp;patients&nbsp;treated&nbsp;with&nbsp;5- FU-containing regimens. The hazard ratio for overall survival was 0.94 (95% CI: 0.89; 1.00, p=0.0489) indicating that capecitabine-containing regimens are non-inferior to 5-FU- containing regimens.</p><p><u>Breast&nbsp;cancer:</u></p><p><em><u>Combination&nbsp;therapy&nbsp;with&nbsp;capecitabine&nbsp;and&nbsp;docetaxel&nbsp;in&nbsp;locally&nbsp;advanced&nbsp;or&nbsp;metastatic&nbsp;breast</u></em><em>&nbsp;<u>cancer</u></em></p><p>Data from one multicentre, randomised, controlled phase III clinical trial support the use of capecitabine incombination&nbsp;with&nbsp;docetaxel&nbsp;for&nbsp;treatment of&nbsp;patients&nbsp;with locally&nbsp;advanced or metastatic&nbsp;breast&nbsp;cancer&nbsp;afterfailure&nbsp;of&nbsp;cytotoxic&nbsp;chemotherapy,&nbsp;including&nbsp;an&nbsp;anthracycline.</p><p>In&nbsp;this&nbsp;trial, 255 patients&nbsp;were&nbsp;ran domised to&nbsp;treatment with&nbsp;capecitabine (1250 mg/m<sup>2</sup>&nbsp;twice daily for 2 weeks followed by 1-week rest period and docetaxel 75 mg/m<sup>2</sup>&nbsp;as a 1 hour intravenous&nbsp;infusion&nbsp;every&nbsp;3&nbsp;weeks).&nbsp;256patients&nbsp;were&nbsp;randomized&nbsp;to&nbsp;treatment&nbsp;with&nbsp;docetaxel alone (100 mg/m<sup>2</sup>&nbsp;as a 1 hour intravenous infusion every 3 weeks).</p><p>Survival&nbsp;was&nbsp;superior&nbsp;in&nbsp;the&nbsp;capecitabine&nbsp;+ docetaxel&nbsp;combination&nbsp;arm&nbsp;(p=0.0126).</p><p>Median&nbsp;survival&nbsp;was&nbsp;442&nbsp;days&nbsp;(capecitabine&nbsp;+&nbsp;docetaxel) vs. 352&nbsp;days (docetaxel&nbsp;alone). The overall objective response rates in the all-randomised population (investigator assessment) were 41.6% (capecitabine + docetaxel) vs. 29.7% (docetaxel alone); p = 0.0058. Time to progressive&nbsp;disease&nbsp;was&nbsp;superior in&nbsp;the&nbsp;capecitabine&nbsp;+docetaxel&nbsp;combination&nbsp;arm&nbsp;(p&lt;0.0001). The median time to progression was 186 days (capecitabine + docetaxel) vs. 128 days (docetaxel alone).</p><p><em><u>Monotherapy with capecitabine after failure of taxanes, anthracycline containing</u></em><em>&nbsp;<u>chemotherapy, and for whom anthracycline therapy is not indicated</u></em></p><p>Data&nbsp;from&nbsp;two&nbsp;multicentre&nbsp;phase&nbsp;II&nbsp;clinical&nbsp;trials&nbsp;support&nbsp;the&nbsp;use&nbsp;of&nbsp;capecitabine&nbsp;monotherapy for&nbsp;treatment&nbsp;ofpatients&nbsp;after&nbsp;failure&nbsp;of&nbsp;taxanes&nbsp;and&nbsp;an&nbsp;anthracycline-containing&nbsp;chemotherapy regimen or for whom further anthracycline therapy is not indicated. In these trials, a total of 236&nbsp;patients&nbsp;were&nbsp;treated&nbsp;with&nbsp;capecitabine&nbsp;(1250mg/m<sup>2</sup>&nbsp;twice&nbsp;daily&nbsp;for&nbsp;2&nbsp;weeks followed by 1-week rest period). The overall&nbsp;objective response rates (investigator assessment) were 20% (first&nbsp;trial)&nbsp;and&nbsp;25%&nbsp;(second&nbsp;trial).&nbsp;The&nbsp;median&nbsp;time&nbsp;to&nbsp;progression&nbsp;was&nbsp;93and&nbsp;98&nbsp;days.&nbsp;Median survival was 384 and 373 days.</p><p><u>All&nbsp;indications:</u></p><p>A&nbsp;meta-analysis&nbsp;of&nbsp;14&nbsp;clinical&nbsp;trials&nbsp;with&nbsp;data&nbsp;from&nbsp;over&nbsp;4700&nbsp;patients&nbsp;treated&nbsp;with&nbsp;capecitabine monotherapy&nbsp;orcapecitabine&nbsp;in&nbsp;combination&nbsp;with&nbsp;different&nbsp;chemotherapy&nbsp;regimens&nbsp;in&nbsp;multiple indications&nbsp;(colon, colorectal, gastric and breast cancer) showed that patients&nbsp;on&nbsp;capecitabine who developed hand-foot syndrome&nbsp;(HFS)&nbsp;had&nbsp;a longer&nbsp;overall&nbsp;survival&nbsp;compared&nbsp;to patients who&nbsp;did&nbsp;not&nbsp;develop&nbsp;HFS:&nbsp;median&nbsp;overall&nbsp;survival&nbsp;1100&nbsp;days&nbsp;(95%CI&nbsp;1007;1200)&nbsp;vs&nbsp;691&nbsp;days (95% CI 638;754) with a hazard ratio of 0.61 (95% CI 0.56; 0.66).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of capecitabine have been evaluated over a dose range of 502-3514 mg/m<sup>2</sup>/day. The parameters of capecitabine, 5&#39;-deoxy-5-fluorocytidine (5&#39;-DFCR) and 5&#39;- deoxy-5-fluorouridine&nbsp;(5&#39;-DFUR)measured&nbsp;on&nbsp;days&nbsp;1&nbsp;and&nbsp;14&nbsp;were&nbsp;similar.&nbsp;The&nbsp;AUC&nbsp;of&nbsp;5-FU&nbsp;was&nbsp;30%-35%&nbsp;higher on&nbsp;day&nbsp;14. Capecitabine dose reduction&nbsp;decreases&nbsp;systemic exposure&nbsp;to 5-FU more than dose-proportionally, due to non-linear pharmacokinetics for the active&nbsp;metabolite.</p><p><u>Absorption</u></p><p>After oral administration, capecitabine is rapidly and extensively absorbed, followed by extensive conversion to the metabolites, 5&#39;-DFCR and 5&#39;-DFUR. Administration with food decreases&nbsp;the&nbsp;rate&nbsp;of&nbsp;capecitabine&nbsp;absorption, but&nbsp;only&nbsp;results in&nbsp;a&nbsp;minor effect&nbsp;on&nbsp;the&nbsp;AUC&nbsp;of 5&#39;-DFUR, and&nbsp;on&nbsp;the AUC&nbsp;of&nbsp;the&nbsp;subsequent metabolite&nbsp;5-FU. At the&nbsp;dose&nbsp;of&nbsp;1250 mg/m<sup>2</sup>&nbsp;on&nbsp;day 14 with administration after food intake, the peak plasma concentrations (Cmax&nbsp;in &mu;g/ml)&nbsp;for capecitabine, 5&#39;-DFCR, 5&#39;-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46&nbsp;respectively. The time to peak plasma concentrations (Tmax&nbsp;in hours) were 1.50, 2.00, 2.00, 2.00 and 3.34. The AUC0-&infin;&nbsp;values in &mu;g&bull;h/ml were 7.75, 7.24, 24.6, 2.03 and 36.3.</p><p><u>Distribution</u></p><p><em>In vitro&nbsp;</em>human plasma studies have determined that capecitabine, 5&#39;-DFCR, 5&#39;-DFUR and 5- FU are 54%, 10%, 62% and 10% protein bound, mainly to albumin.</p><p><u>Biotransformation</u></p><p>Capecitabine is first metabolised by hepatic carboxylesterase to 5&#39;-DFCR, which is then converted to 5&#39;-DFUR by cytidine deaminase, principally located in the liver and tumour tissues. Further catalytic activation of 5&#39;-DFUR then occurs by thymidine phosphorylase (ThyPase). The enzymes involved in the catalytic activation are found in tumour tissues but also in normal tissues, albeit usually at lower levels. The sequential enzymatic biotransformation of capecitabine to 5-FU leads to higher concentrations within tumour tissues.&nbsp;In&nbsp;the&nbsp;case&nbsp;ofcolorectal&nbsp;tumours,&nbsp;5-FU&nbsp;generation&nbsp;appears&nbsp;to&nbsp;be&nbsp;in&nbsp;large&nbsp;part&nbsp;localised in tumour stromal cells. Following oral administration of capecitabine to patients with colorectal&nbsp;cancer,&nbsp;the&nbsp;ratio&nbsp;of&nbsp;5-FU&nbsp;concentration&nbsp;in&nbsp;colorectaltumours&nbsp;to&nbsp;adjacent&nbsp;tissues&nbsp;was</p><p>3.2 (ranged from 0.9 to 8.0). The ratio of 5-FU concentration in tumour to plasma was 21.4 (ranged from&nbsp;3.9&nbsp;to 59.9, n=8) whereas the ratio in healthy&nbsp;tissues to plasma was 8.9 (ranged from 3.0 to 25.8, n=8). Thymidine phosphorylase activity was measured and found to be 4 times&nbsp;greater&nbsp;in&nbsp;primary&nbsp;colorectal&nbsp;tumour&nbsp;than&nbsp;inadjacent&nbsp;normal&nbsp;tissue.&nbsp;According&nbsp;to&nbsp;immunohistochemical studies, thymidine phosphorylase appears to be in large part localised in tumour stromal cells.</p><p>5-FU is further catabolised by the enzyme dihydropyrimidine dehydrogenase (DPD) to the much less toxic dihydro-5-fluorouracil&nbsp;(FUH2). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureidopropionic acid (FUPA). Finally, &beta;-ureido-propionase cleaves FUPA to &alpha;-fluoro-&beta;-alanine (FBAL) which is cleared in the urine. Dihydropyrimidine dehydrogenase (DPD) activity is the rate limiting step. Deficiency of DPD may lead to increased toxicity of capecitabine (see section 4.3 and 4.4).</p><p><u>Elimination</u></p><p>The elimination half-life (t1/2&nbsp;in hours) of&nbsp;capecitabine, 5&#39;-DFCR, 5&#39;-DFUR, 5-FU and FBAL&nbsp;were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively. Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Faecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL, which&nbsp;represents&nbsp;57%&nbsp;of&nbsp;the&nbsp;administered&nbsp;dose.&nbsp;About&nbsp;3%&nbsp;of&nbsp;the&nbsp;administered&nbsp;dose&nbsp;isexcreted in urine unchanged.</p><p><u>Combination&nbsp;therapy</u></p><p>Phase I studies evaluating the effect of capecitabine on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by capecitabine on the&nbsp;pharmacokinetics of docetaxel or paclitaxel (Cmax&nbsp;and AUC) and no effect by docetaxel or&nbsp;paclitaxel on the pharmacokinetics of 5&#39;-DFUR.</p><p><u>Pharmacokinetics&nbsp;in&nbsp;special&nbsp;populations</u></p><p>A population pharmacokinetic analysis was carried out after capecitabine treatment of 505 patients&nbsp;withcolorectal&nbsp;cancer&nbsp;dosed&nbsp;at&nbsp;1250&nbsp;mg/m<sup>2</sup>&nbsp;twice&nbsp;daily.&nbsp;Gender,&nbsp;presence&nbsp;or&nbsp;absence of&nbsp;liver metastasis at baseline, Karnofsky&nbsp;Performance Status, total&nbsp;bilirubin, serum&nbsp;albumin, ASAT and ALAT had no statistically&nbsp;significant effect on&nbsp;the pharmacokinetics&nbsp;of&nbsp;5&#39;-DFUR, 5-FU and FBAL.</p><p>Patients with hepatic impairment due to liver metastases: According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability&nbsp;of&nbsp;capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment. There are no pharmacokinetic data on patients with severe hepatic&nbsp;impairment.</p><p><u>Patients&nbsp;with&nbsp;renal&nbsp;impairment:</u>&nbsp;Based&nbsp;on&nbsp;a&nbsp;pharmacokinetic&nbsp;study&nbsp;in&nbsp;cancer&nbsp;patients&nbsp;with&nbsp;mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU. Creatinine clearance was found to influence the systemic&nbsp;exposure&nbsp;to&nbsp;5&#39;-DFUR&nbsp;(35%&nbsp;increase in&nbsp;AUCwhen&nbsp;creatinine&nbsp;clearance&nbsp;decreases&nbsp;by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%). FBAL is a metabolite without antiproliferative activity.</p><p><u>Elderly:</u>&nbsp;Based on the population pharmacokinetic analysis, which included patients with a wide&nbsp;range&nbsp;of&nbsp;ages(27&nbsp;to&nbsp;86&nbsp;years)&nbsp;and&nbsp;included&nbsp;234&nbsp;(46%)&nbsp;patients&nbsp;greater&nbsp;or&nbsp;equal&nbsp;to&nbsp;65,&nbsp;age has&nbsp;no&nbsp;influence&nbsp;on&nbsp;thepharmacokinetics&nbsp;of&nbsp;5&#39;-DFUR&nbsp;and&nbsp;5-FU.&nbsp;The&nbsp;AUC&nbsp;of&nbsp;FBAL&nbsp;increased with age (20% increase in age results in a 15% increase in the AUC of FBAL).</p><p>This&nbsp;increase&nbsp;is&nbsp;likely&nbsp;due&nbsp;to&nbsp;a&nbsp;change&nbsp;in&nbsp;renal&nbsp;function.</p><p>&nbsp;</p><p><u>Ethnic factors</u>: Following oral administration of 825 mg/m2 capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for&nbsp;capecitabine&nbsp;than&nbsp;Caucasian&nbsp;patients(n=22).&nbsp;Japanese&nbsp;patients&nbsp;had&nbsp;also&nbsp;about&nbsp;25%&nbsp;lower&nbsp;Cmax&nbsp;and 34% lower AUC for FBAL than Caucasian patients. The clinical relevance of these differences is unknown. No significant differences occurred in the exposure to other metabolites (5&#39;-DFCR, 5&#39;- DFUR, and 5-FU).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat-dose toxicity studies, daily oral administration of capecitabine to cynomolgus monkeys&nbsp;and mice produced&nbsp;toxic effects&nbsp;on&nbsp;the gastrointestinal, lymphoid and haemopoietic systems, typical for fluoropyrimidines. These toxicities were reversible. Skin toxicity, characterised by degenerative/regressive changes, was observed with capecitabine.</p><p>Capecitabine&nbsp;was&nbsp;devoid&nbsp;of&nbsp;hepatic&nbsp;and CNS&nbsp;toxicities. Cardiovascular&nbsp;toxicity&nbsp;(e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m<sup>2</sup>/day).</p><p>A two-year mouse carcinogenicity study produced no evidence of carcinogenicity by&nbsp;capecitabine.</p><p>During&nbsp;standard&nbsp;fertility&nbsp;studies,&nbsp;impairment&nbsp;of&nbsp;fertility&nbsp;was&nbsp;observed&nbsp;in&nbsp;female&nbsp;mice&nbsp;receiving capecitabine;however,&nbsp;this&nbsp;effect&nbsp;was&nbsp;reversible&nbsp;after&nbsp;a&nbsp;drug-free&nbsp;period.&nbsp;In&nbsp;addition,&nbsp;during&nbsp;a&nbsp;13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6).</p><p>In&nbsp;embryotoxicity&nbsp;and&nbsp;teratogenicity&nbsp;studies&nbsp;in&nbsp;mice,&nbsp;dose-related&nbsp;increases&nbsp;in&nbsp;foetal&nbsp;resorption and&nbsp;teratogenicitywere&nbsp;observed.&nbsp;In&nbsp;monkeys,&nbsp;abortion&nbsp;and&nbsp;embryolethality&nbsp;were&nbsp;observed&nbsp;at high doses, but there was no evidence of teratogenicity.</p><p>Capecitabine&nbsp;was&nbsp;not mutagenic&nbsp;<em>in&nbsp;vitro&nbsp;</em>to bacteria&nbsp;(Ames&nbsp;test)&nbsp;or&nbsp;mammalian&nbsp;cells&nbsp;(Chinese hamsterV79/HPRT&nbsp;gene&nbsp;mutation&nbsp;assay).&nbsp;However,&nbsp;similar&nbsp;to&nbsp;other&nbsp;nucleoside&nbsp;analogues&nbsp;(ie, 5-FU), capecitabine was clastogenic in human lymphocytes (<em>in vitro</em>) and a positive trend occurred in mouse bone marrow micronucleus tests (<em>in vivo</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet&nbsp;core:</em></p><p>Anhydrous&nbsp;lactose,&nbsp;Croscarmellose&nbsp;sodium,&nbsp;Hydroxypropy&nbsp;methylcellulose,&nbsp;Microcrystalline cellulose, Magnesium stearate.</p><p><em>Tablet&nbsp;coating:</em></p><p>Hypromellose,&nbsp;Titanium&nbsp;dioxide,&nbsp;Yellow&nbsp;and&nbsp;Red&nbsp;iron&nbsp;oxide,&nbsp;Talc,&nbsp;Ferrosoferric&nbsp;oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do&nbsp;not&nbsp;store&nbsp;above&nbsp;30&ordm;C.&nbsp;Protect&nbsp;from&nbsp;light&nbsp;and&nbsp;moisture.&nbsp;</p><p>Keep&nbsp;out&nbsp;of&nbsp;reach&nbsp;of&nbsp;children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Light peach to peach colored, oblong shaped biconvex film coated tablets, debossed with&nbsp;&quot;C&quot; on one side and &quot;500&quot; on other side. 10 tablets of EMCAP are packed in Alu-Alu blister pack and such 10 blister packs are packed in secondary packaging printed carton along with Package insert.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Procedures&nbsp;for safe&nbsp;handling of&nbsp;cytotoxic&nbsp;drugs&nbsp;should&nbsp;be&nbsp;followed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company,
Sudair Industrial Zone,
Sudair,
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>